Tender Ref. No.: BPPI/DRUG/RC-159/2021 **Dated: 13/01/2021**

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA

(Set up under the Department of Pharmaceuticals, Govt. of India)

8th Floor, Videocon Tower, Block E1
Jhandewalan Extension, New Delhi-110055
Telephone: 011- 011-49431800/49431812/49431829/49431854

Website: janaushadhi.gov.in

e- TENDER FOR SUPPLY OF DRUGS

TO

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA (BPPI) FOR TWO YEARS

RATE CONTRACT

LAST DATE FOR ONLINE SUBMISSION OF TENDER: 03/02/2021

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA (BPPI)

(SET UP UNDER THE DEPARTMENT OF PHARMACEUTICALS, GOVERNMENT OF INDIA)

Regd. Office: Core No. 6, First Floor, SCOPE Complex, Lodi Road, New Delhi-110003

Working Office: 8th Floor, Videocon Tower, Block E1, Jhandewalan Extension, New Delhi-110055

Telephone: 011- 49431800/49431812/49431829/49431854.

Website: **janaushadhi.gov.in**

e-TENDER FOR TWO YEARS RATE CONTRACT

FOR SUPPLY OF DRUGS TO BUREAU OF PHARMA PSU OF INDIA

Tender Reference		**BPPI/DRUG/RC-159/2021, Date-13/01/2021**
Tender Website		**https://eprocure.gov.in**
Date of availability of tender documents on website		**On 13/01/2021(Wednesday)**
Doubts and queries regarding Tender document should be sent by e-mail-to-e-mail id "proc6@janaushadhi.gov.in, proc9@janausadhi.gov.in, proc8@janausadhi.gov.in" by the likely bidders latest by		**On 20/01/2021 upto 17.00 Hours**
Time and date and place pre-bid meeting		**On 21/01/2021(Thursday) at 11:00 AM** Bureau of Pharma **PSUs** of India, 8th Floor, Videocon Tower, Block-E1, Jhandewalan Extension, New Delhi-110055
Last date and time for submission of Online Bid i.e., Bid Submission End Date and time		**On 03/02/2021 up to 17.00 Hours.**
Last Date and time for submission of *Bid Security Declaration and Original Required Documents as per ANNEXURE I (Check List), in physical Form* in office of Bureau of Pharma PSUs of India, 8th Floor, Videocon Tower, Block-E1, Jhandewalan Extension, New Delhi-110055		**On 08/02/2021 by 17.00 Hours**
Time and date of opening of Technical Bid		**On 09/02/2021 at 11.30 Hours (Tuesday)**
Place of opening of tender		**Bureau of Pharma PSUs of India,** 8th Floor, Videocon Tower, Block-E1, Jhandewalan Extension, New Delhi-110055

Opening of Tender		Online on https://eprocure.gov.in
Address for Communication		**Bureau of Pharma PSUs of India,** 8th Floor, Videocon Tower, Block-E1, Jhandewalan Extension, New Delhi-110055
Cost of the Tender Document		**Free of cost**
Contact Person for clarification if any		1. Sh. P. K. Thakur Sr. Executive (Procurement) Phone: - 011-49431829 Email: - proc6@janaushadhi.gov.in
		2. Sh. Manik Bera, Dy. Manager (Procurement) Phone: - 011-49431854 Email: - proc9@janaushadhi.gov.in
		3. Sh. Pritam Singh Manager (Procurement) Phone: - 011-49431812 Email: - proc8@janaushadhi.gov.in

The tender document can be downloaded free of cost from the CPPP e-Procurement Portal https://eprocure.gov.in and from *the website of BPPI:* ***janaushadhi.gov.in.***

Note: ***The bidders shall be solely responsible for checking these websites at least 3 days prior to closing date of submission of tender for any addendum/amendment issued subsequently to the bid document and take into consideration the same while preparing and submitting the bids. Bids will be opened online.***

TABLE OF CONTENTS

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA (BPPI)

e-TENDER FOR RATE CONTRACT FOR THE SUPPLY OF DRUGS TO

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA (BPPI)

PRADHAN MANTRI BHARTIYA JANAUSHADHI PARIYOJANA (PMBJP) is the initiative of Department of Pharmaceuticals, Ministry of Chemical and Fertilizer, Government of India launching with the noble objective of making quality generic medicines available at affordable prices for all, particularly the poor and disadvantaged, through specialized outlets called PRADHAN MANTRI BHARTRIYA JANAUSHADHI KENDRA (PMBJK). BPPI was established in December 2008 under the Department of Pharmaceuticals, Government of India, with the support of all the CPSUs, and identified as the executing agency for PMBJP.

The Bureau has been registered as an independent society under the Societies Registration Act, 1860, in April 2010.

At present, more than ***7000 stores*** are functional. It is proposed to channelize efforts to popularize PMBJP and ensure availability of the complete basket of medicines at affordable prices.

Tender Inviting Authority – C.E.O, Bureau of Pharma Public Sector Undertakings of India, 8th Floor, Videocon Tower, Block E1, Jhandewalan Extension, New Delhi-110055 (hereinafter referred as **Tender Inviting Authority** unless the context otherwise requires).

Tender Accepting Authority – CEO, Bureau of Pharma Public Sector Undertakings of India (hereinafter referred as **BPPI** unless the context otherwise requires).

Tender Inviting Authority Invites **Tender for the supply of Drugs to BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA for Two Years.**

1.TENDERING SYSTEM:

The Bids are to be submitted in two Parts i.e.

i. Technical Bid **(Cover "A")**
ii. Financial Bid / Price Bid **(Cover "B")**

i. The **TECHNICAL BID** shall contain the complete technical details of the firm and the documents to provide the eligibility and competency of the bidder and shall be submitted online only in the manner prescribed in Bid document.

The documents like Tender Document and Bid Security Declaration shall be submitted before the specified schedule at the office of BPPI super scribed, **"Tender Documents &** Bid Security Declaration **for Tender Reference No.-BPPI/DRUG/RC-159/2021 dated 13/01/2021 for the procurement of Drugs for the year 2021-2023".** However complete hard copy of uploaded tender shall be provided by the bidder firm along-with the mandatory required documents as per clause 3 of Bid and Bid Security Declaration for evaluation purpose only. This hard copy shall under no case substitute/modify the provisions of e-tender system.

ii. The **Financial Bid/Price Bid** shall be valid for a period of 150 days from the date of opening of Technical Bid. Prior to the expiry of the bid validity, the Tender Inviting Authority may request the Tenderers to extend the bid validity for further period as deemed fit on their original quoted prices and all terms & conditions. However, BPPI reserves the right to place purchase orders at the quoted rate till such period.

a) The Tenderer shall fill in the rate per unit size, % age rate of GST in respective column of BOQ for the items quoted**.**

b) In determining the lowest evaluated price, the rate quoted per unit size exclusive of GST as indicated in column No. 7 of the **BOQ** shall be taken into consideration.

c) Tender has been called for in the **Generic name of drugs**. The Tenderers should quote the rates for the generic products only. The composition, strength and packing of each product should be as per specifications given in **ANNEXURE-XII** and Shape, Colour, Packing Type etc. of drugs should be as per **ANNEXURE XIV** (attached). Any variation, if found, will result in rejection of the tender.

d) Rates (inclusive of customs duty, packing & forwarding charges, transportation, insurance and any incidental charges, but exclusive **GST** should be quoted for each of the required drugs, medicines etc., on door delivery basis according to the unit ordered. Tender for the supply of drugs, medicines, etc. with cross conditions like "AT CURRENT MARKET RATES" shall not be accepted. Handling, clearing, transport charges etc., will not be paid separately. The delivery should be made as stipulated in the purchase order placed with Tenderers.

e) The price quoted by the tenderers shall not, in any case exceed the DPCO controlled price, if any, fixed by the Central/State Government, the Maximum Retail Price (MRP) and the selling price of the tenderer.

In case any tenderer quotes higher than the DPCO controlled price, competent authority shall be informed for appropriate action.

2. LAST DATE AND TIME FOR SUBMISSION OF ONLINE TENDER:

i. (a) Online Bids [in two separate Cover {Technical bid (Cover "A") and price bid (Cover "B")}] shall be submitted/uploaded till 17.00 Hours Up to 03/02/2021 (Wednesday) on CPP portal i.e., https://eprocure.gov.in.

(b) Hard copy of complete required documents as Per Clause 3. Eligibility Criteria of Bid and Bid Security Declaration shall be submitted as before the specified schedule at the below mentioned address of BPPI with super scribed, **"Tender Document &** Bid Security Declaration **for Tender Reference No.-BPPI/DRUG/RC-159/2021 dated 13/01/2021 for the procurement of Drugs for the year 2021-2023"**

"To,
The Chief Executive Officer
Bureau of Pharma PSUs of India, (BPPI)
8th Floor, Videocon Tower, Block-E1,
Jhandewalan Extension, New Delhi-110055"

ii. **Late Tender:** -There is NO PROVISION of uploading late tender beyond stipulated date & time in the e-tendering system.

3. ELIGIBILITY CRITERIA (TECHNICAL BID -COVER "A"):

Minimum Eligibility criteria along with list of documents to be submitted in Cover 'A'. Bidders should meet the following criteria to be eligible for bidding and relevant papers/documents must be submitted by them in their technical bid (Cover- 'A') in support of their eligibility for the tender.

A) Bidder should sign a **Bid Security Declaration** accepting that if they withdraw or modify their bids during the period of validity, or if they are awarded the contract and if they fail to obliged/adhere the tender condition/ provision made in the bid document, they will be suspended for the period of two (2) years from the date of disqualification.

Note: The Micro and Small enterprises (MSEs) and the firms registered with National Small Industries Corporation (NSIC) etc. are exempted from submitting the Bid Security as per prevailing rules. However, they have to submit the valid documentary evidence in support of MSE/Registration with NSIC (indicating the items for which they are registered.) along with the technical bid.

B) Documentary evidence of the constitution of the company/firm/Proprietorship such as Memorandum and Articles of Association, Partnership Deed etc. should be submitted with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director / Partners / Proprietor should be submitted.

C) Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidding firm to sign the documents should be submitted.

D) Bidders must have: -
   a) Minimum three years old valid Manufacturing License of the product quoted with latest license renewal certificate.
   b) Approved product list as per the license issued for quoted drugs for minimum three years.
   c) Manufacturing License along with approved product list must be valid till the last date of the submission of tender.

d) In Case of those drugs which are notified first time in IP 2018 & IP Addendum 2019 then Manufacturing and Marketing license should be in any official compendium (USP/BP/IP) along with current valid License in IP in continuation.

e) Market standing certificate & Manufacturing certificate issued by the Licensing Authority as a Manufacturer for each drug quoted for the last 3 years (Certificate should be enclosed with list of items) except for the drugs falling under the category of **'New Drug'** as defined by CDSCO (Central Drugs Standard Control Organisation). If permission in Form 46 from DCGI has been obtained, then the 3 years Manufacturing & Market standing clause will be relaxed. The provisions of Rule 122 E of Drugs and Cosmetics Act rule 1945 shall be applicable.

f) FFS (Flow Fill & Seal Process) Technology will be accepted wherever applicable.

Note: If Manufacturing License for the quoted product is issued under "for export only" category will not be accepted.

Bidders shall submit dully attested copies of required manufacturing license and approved product list in support of above-mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it.

E) Bidder must have Market Standing Certificate (in India) of minimum two batches of quoted product in last three years issued by the concerned Licensing Authority from Drugs Control Department for the quoted product. Self-attested copies are to be submitted.

F) Non-Conviction Certificate (NCC) issued by the concerned Licensing of the state certifying that the firm/company has not been convicted in last three years should be submitted. It should be not more than 12 months old. Self-attested copies are to be submitted.

G) WHO-GMP (WHO-Good Manufacturing Practice) as per revised Schedule- 'M'/COPP Certificate of the manufacturing unit issued by the Licensing Authority/ Drugs Control Department. The WHO-GMP certificate must be valid as on the last date of submission of tender. Self-attested copies are to be submitted in hard copy.

H) Maximum Production Capacity Certificate (section wise) issued by concerned Licensing Authority Form Drugs Control Department highlighting the quoted product section. Self-attested copies are to be submitted.

I) Copies of the Audited Balance Sheet, Profit and Loss statement showing details of their annual average turnover for any three of the last four consecutive financial years not less than **25 Crores (Twenty-Five crore).** In case of loan licensee average annual turnover of manufacturing unit/ Host Company for any three of the last four consecutive financial years not less than **25 Crores (Twenty-Five crore).** Details shall be provided in per Annexure IV. Self-attested copies are to be submitted.

J) Declaration **On nonjudicial Stamp Paper** for eligibility in participating the tender for quoted drugs in prescribed format as per **Annexure-II.**

K) Tenderer shall furnish Company's bank details as per Annexure V (Mandate Form).

L) Tenderers are required to submit **Annexure-VI** indicating details of manufacturing License and three years Market Standing Certificate (MSC) as mentioned there in.

M) Tenderer are required to submit declaration duly signed to supply the drugs as per the design in enclosure 1 and enclosure 2 in Annexure VII as well as other instructions given in this regard.

N) Duly attested Checklist as per (**ANNEXURE- I**) shall be submitted.

O) Copy of PAN Card of the bidder company should be submitted (self-attested).

P) Copy of certificate of valid GST registration of the bidder company should be submitted (self-attested).

Q) Copy of Income Tax Return for any three of last four Consecutive Assessment years should be submitted (self-attested).

R) Duly attested Copy of valid GS-1 registration certificate from GS1 India.

S) The copies of relevant pages approved by drug authorities of concerned country for any quoted Drug/ products manufactured by manufacturing units approved by US FDA, TG Australia, Health Canada, EU approval, MCC South Africa approval, Brazil Anvisa (if any) should be uploaded with technical bid.

Note: -

(i) The certificates/ reports / annexure submitted with the bid document should be self-attested by the authorized signatory of the firm with official seal, wherever required.

ii) Technical evaluation of the Bid will be done on the basis of the above-mentioned criteria and documents mentioned in Clause no. 3 (TECHNICAL BID- COVER 'A') Mandatory Documents shall be submitted online only at CPPP portal: https://eprocure.gov.in Failing which the bid will not be considered for technical evaluation.

iii) Hard copy of required documents uploaded shall be submitted along with Bid Security Declaration and other required documents on or before the last day of submission of tender for purely evaluation purposes. However, the submission of hard copy of uploaded tender document submitted shall not substitute/modify the provisions of e-tendering system.

iv) The technical evaluation shall be done only on the basis of documents/papers submitted by the bidder on https://eprocure.gov.in

v) Clear copy of valid drug license highlighting the drug code should be uploaded. In case scanned copy of license uploaded is not visible or tempered, BPPI shall not considered the license for such drug.

4. GENERAL CONDITIONS:

A) Tender bid is invited directly from Manufacturers in India. Loan licensee is also eligible. Distributors/agents/contract manufacturers/Importers are not eligible to participate in the tender.

B) Manufacturer has Production & financial capacity to manufacture and deliver the drugs quoted by the firm in the tender as per quantity mentioned in tender during contract period.

C) Bidders are advised to quote only for such drugs which meets the drug specification as mentioned in Annexure XII. Do not quote if it differs with regard to any parameter.

D) The quantities specified in the tender is for the tender purpose only and it represents the basis of unit for ease of pricing. The actual quantity may vary from zero to the maximum required quantity during the contract. The quantity will be drawn from successful tenderers as and when required from time to time during the contract period.

E) STP (Standard Testing Procedure) for Non- Pharmacopoeia awarded drugs are required to submit within 15 days from the date of Letter of Acceptance.

F) The bidder shall submit the complete stability data (long term stability studies and accelerated stability studies) for all awarded drugs whenever required by the BPPI. For New drugs, complete stability data of 6 months' period shall be acceptable. (If manufacturer has licensed a formula from another company and such licensed formula is used for the product, then the stability data of the licensor should be submitted along with licensing agreement.)

G) The manufacturer shall declare the active API polymorphic form used in formulation for all quoted drugs and declare that it is internationally accepted active polymorph when ask by BPPI.

H) The Tenderer should have not been blacklisted/debarred/de-registered/banned due to quality failure for the quoted product /firm by any State Government / Central Government/ BPPI/Central or State Government's Drug procurement agencies **at the time of submission of bid**. Further, quoted drugs have not been failed in house testing or testing by any State Government/Central Government / its Drug procurement agencies/BPPI during last two years. If any tenderer has been blacklisted/debarred/de-registered/banned due to quality failure, such tenderer or their Partner/Director/Owner shall not be permitted to participate in the tender.

I) During the validity of the tender if the firm / Company is blacklisted/debarred/de-registered/banned by any State Government/ Central Government/ BPPI/ Central or State Government's Drug procurement agencies / convicted by any Court of law in India, it shall be intimated to BPPI along with relevant authentic document by the tenderer firm/ company within one month.

J) During tender or Rate Contract period, if L1 bidder is debarred/deregistered /blacklisted/ banned by any Central Government or State Government or its procurement agencies due to quality failure, BPPI may purchase the drugs from other bidders at L1 rate or may go for fresh tender as per discretion of BPPI.

K) The BPPI reserves the right to purchase any drugs from PSUs as per discretion of BPPI. In case of emergencies, BPPI may go to PSUs and price will be as per negotiation and at the discretion of BPPI.

L) The Tenderer should confirm that they have read tender document including Amendment(s) to Tender document (if any) along with terms and condition and these terms and condition of tender document including Amendment(s) to Tender document (if any) are acceptable unconditionally to them.

M) Validity of Rate Contract: -The rate contract will be applicable for 2(two) year from the date of acceptance of LOA. The validity of contract may be extended with mutual consent for some specified period to the maximum of 1(one) year by BPPI, if necessary.

N) During the contract period at any stage, if certificate submitted with their bid is found fabricated/forged/not complying products manufactured by manufacturing units having approval of the any agency like US FDA, TG Australia, Health Canada, EU, MCC South Africa approval, Brazil Anvisa as declared in tender, penal action shall be taken as per the tender terms and condition and in addition to penal action, recovery shall be made (if any).

O) If a company/firm has two or more separate manufacturing units at different sites / States, which are not separate entities then the company will be allowed to submit only one tender for all units but necessary document regarding separate manufacturing units will uploaded as a separate set with the same tender. However, one bidder will be allowed to submit only one offer for one product.

P) Only authorized employee of the Company/Tenderer will be allowed to transact the business with the Tender Inviting Authority.

5. PRICE BID – "COVER-B" (Financial Bid/BOQ)

A) Cover "B" (Financial Bid/BOQ) contains the Price Bid of the Tenderer. The Tenderer shall fill in the rate per unit size, % age rate of GST in respective column of BOQ for the items quoted**.**

B) **Determination of L1 Bidder:**

a) In determining the lowest evaluated price, the rate quoted per unit size for the given specification, exclusive of GST as indicated in column No. 7 of the **BOQ** shall be taken into consideration. **The rates quoted should be in rupees and paisa up to 2 digits.** The Tenderer is not permitted to change/alter specification or unit size given in the **ANNEXURE-XII.**

b) **GST (Goods and Services Tax)-The Tenderers must indicate the rate of GST applicable and payable by them. In case no information is given, it shall be presumed that rate is inclusive of GST and no GST shall be charged by them under any circumstances.**

c) **The bidder is required to indicate rate of GST (%) as digit only in column 9 of BOQ without suffixing the % sign and not to indicate amount of GST in Rs. at particular cell of excel sheet of BOQ.**

d) Purchase preference shall be given over acceptable L1 bidder to bidder **offering Products manufactured by manufacturing units approved by US FDA, TG Australia, Health Canada, EU approval, MCC South Africa approval, Brazil Anvisa subject to matching of** acceptable L1 rate.

e) (i) If the participating Micro and Small Enterprises (MSE) meets all the other eligibility criteria and their quoting price is within price band of L1+15 (fifteen) per cent shall also be allowed to supply a portion of requirement by bringing down their price to L1 price in a situation where L1 price is from someone other than a MSE and such MSE shall be allowed to supply up to 20 (twenty) per cent of total tendered value. The 20 (twenty) per cent quantity is to be distributed proportionately among these bidders, in case there are more than one MSEs within such price band.

(ii) Within this 20% (Twenty Percent) quantity, a purchase preference of four per cent (that is, 20 (twenty) per cent out of 20 (twenty) per cent) will be reserved for MSEs owned by Scheduled Caste (SC)/Scheduled Tribe (ST) entrepreneurs (if they participate in the tender process and match the L1 price). Provided that, in event of failure of such SC/ST MSE to participate in tender process or meet tender requirements and L1 price, four per cent sub-target shall be met from other MSE. MSEs would be treated as owned by SC/ ST entrepreneurs: a) In case of proprietary MSE, proprietor(s) shall be SC /ST b) In case of partnership MSE, the SC/ST partners shall be holding at least 51% (fifty-one percent) shares in the unit c) In case of Private Limited Companies, at least 51% (fifty-one percent) share shall be held by SC/ST promoters.

6. EARNEST MONEY DEPOSIT/ BID SECURITY DECLARATION:

A) Bidder should sign a BID SECURITY DECLARATION accepting that if they withdraw or modify their bids during the period of validity, or if they are awarded the contract and if they fail to obliged/adhere the tender condition/ provision made in the bid document, they will be suspended/disqualified for the period of two (2) years from the date of disqualification. In the absence of BID SECURITY DECLARATION in the prescribed proforma (Annexure- X), the tenders will be rejected.

B) The Micro and Small enterprises (MSEs) and the firms registered with National Small Industries Corporation (NSIC) etc. are exempted from submitting the Bid Security as per prevailing rules. However, they have to submit the valid documentary evidence in support of MSE/Registration with NSIC (indicating the items for which they are registered.) along with the technical bid.

C) PSUs are exempted from the submission of BID SECURITY DECLARATION.

D) The tender submitted without BID SECURITY DECLARATION in the prescribed proforma (Annexure-X) will be summarily rejected.

E) **The bid of the Tender will be suspended/disqualified without further notice if:**

a) If the tenderer withdraws his bid any time after opening of price bid.
b) On refusal to supply medicine after the award of contract/Letter of Acceptance (LOA).
c) In case of the lowest bidder (L1 bidder), fails to execute the contract or fails to complete the first supply successfully within the stipulated time.
d) If the undertaking as Annexure II is not found correct at any stage during the contract period.

7. GUIDELINES FOR THE PREPARATION OF TENDER:

A) The bidder shall bear all costs associated with the preparation and submission of its bid and Tender Inviting Authority will in no case be responsible or liable for these costs, regardless of the conduct or outcome of the bidding process.

B) **Language of Bid: -** The Bid prepared by the bidder and all correspondence and documents relating to the bid exchanged by the bidder and the Tender Inviting Authority, shall be in English language, Supporting documents furnished by the bidder may be in other languages provided they are accompanied by an authenticated (by the authority concerned) accurate translation of the relevant passages in the English language in which case, for purposes of interpretation of the Bid, the English translation shall alone govern. Failure to submit authentic translation of documents would result in rejection of bids. No bid can be partly in one language and partly in another language.

C) Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm should sign the documents in cases where person other than the Managing Director/Managing Partner or sole Proprietor signs the document.

8. PERIOD OF VALIDITY OF TENDER:

a) The tender must remain valid for minimum 150 days from the date of opening of Technical Bid. (As mentioned in Clause 1.ii)

b) Prior to the expiration of the bid validity the Tender Inviting Authority may extend the bid validity for further period with mutual consent of the bidder.

c) The bidder who has extended the bid validity is not required or permitted to modify its bid.

d) The bidder cannot withdraw the bid within validity of Tender.

9. AMENDMENT OF TENDER DOCUMENTS:

At any time prior to the last date of submission of online bid, Tender Inviting Authority may, for any reason, whether on own initiative or in response to a clarification requested by a prospective Tenderer, may modify the condition in Tender documents by uploading an amendment on BPPI website: ***www.janaushadhi.gov.in;*** and on CPP portal i.e. ***https://eprocure.gov.in*** will be binding on them. In order to provide reasonable time to take the amendment into account in preparing their bid, Tender Inviting Authority may at discretion, extend the date and time for submission of online bid.

A) Bidders are advised to check the *website of BPPI:* ***www.janaushadhi.gov.in;*** and CPP Portal i.e., ***https://eprocure.gov.in***; *regularly* at least 3 days prior to closing date of submission of tender for any corrigendum or amendment to the tender document.

B) BPPI will not issue separate communication for any corrigendum or amendment.

10. METHOD OF SUBMISSION OF TENDER:

A) The tender document shall be downloaded from the websites janaushadhi.gov.in; and CPP portal i.e. https://eprocure.gov.in. Tender Document is free of cost. No tender cost is to be deposited

B) Bids shall be submitted online only at CPP Portal i.e., ***https://eprocure.gov.in.*** Manual bids shall not be accepted except for the original documents/instruments as mentioned in Clause 3 of tender document.

C) Bidders are advised to follow the 'Special Instructions to the Contractors/Bidders for the e-submission of the bids online' available through the link 'Help for Contractors' at the e-Procurement Portal https://eprocure.gov.in.

D) If a particular document/Certificate to be uploaded as specified in bid, is not applicable for a bidder, the bidder shall attach a scanned copy of declaration in the letter head stating that the specific document is not applicable/exempted for the bidder in connection to this tender.

E) Bidder shall not modify the downloaded tender form including downloaded price Bid template in any manner. In case any tender form/Price bid template is found to be tampered with/modified in any manner, such bid will be summarily rejected, Bid Security would be forfeited, and bidder is liable to be banned from doing business with BPPI.

F) Interested eligible Tenderer may obtain further information in this regard from the office of the Tender Inviting Authority on all working days between 10:00 AM and 5:00 PM.

G) Once the bid have been uploaded in the CPP Portal https://eprocure.gov.in the bidder has to make sure that he has uploaded the files in the correct format and the bidder has to download the uploaded files from their own end and has to check whether the files uploaded is in proper format or not, no corrupted files have to be uploaded.

11. MODIFICATION AND WITHDRAWAL OF BIDS:

A) The bidder may modify or withdraw its bid after the bid submission before last time and date of submission of online Technical Bid.

B) No bid will be allowed to be withdrawn after the last date & time of submission of online Technical Bids.

12. OPENING OF TENDER:

A) The opening of the Technical Bid and the Price Bid will be done online as specified. The date of technical bid opening is published in advance. The date of opening of price bid will be announced only after the opening and evaluation of Technical bid. The bidder who are found eligible and on satisfying the criteria for technical evaluation/based on undertakings & Declaration, will only be informed the time and date of opening of Price Bid - Cover "B" of the tender.

B) Only authorized employee of tenderer is entitled to be present at the time of opening of Technical Bid - Cover "A" of the tender submitted by them.

C) In case, the date for opening of technical bid is declared holiday, the technical bid shall be opened on next working day at 11.30 A.M.

D) The original/attested hard copies (as mentioned in Clause no. 3, eligibility criteria) must reach the BPPI Head office on or before stipulated time, failing which the bid shall be summarily rejected.

13. EVALUATION OF TENDER:

A) Technical evaluation of the Bid will be done on the basis of criteria and documents mentioned in S.N. 3 (TECHNICAL BID-COVER A) & Annexure I (Check List) which are present in the CPP Portal i.e. https://eprocure.gov.in.

B) Bids of firms who have furnished all the required documents for each of the product quoted will be considered.

C) If at any stage, it is found that the contract has been successfully obtained by the bidder by submitting forged/fabricated certificates/documents/licenses and/or by concealing the fact about blacklisting/debarring/de-registration of the firm by Govt. of India/Suspension/Cancellation/non-renewal of the manufacturing license of the bidder firm, the tender bid/rate contract may be rejected/terminated and suitable punitive action may be taken against the firm.

D) **In event of financial bid opening, due to provisions/compulsion of e-tendering system if complete quoted product list of financial bids of a bidder is opened then only those financial bids of quoted product shall be considered of whose technical bid has been found eligible by the Technical Evaluation Committee**.

E) **After evaluation of technical bid of tenderer/bidder, BPPI may ask the objection/clarification from tenderer/ bidder**.

14. INSPECTION OF MANUFACTURING FACILITIES:

A) BPPI or its authorized representative(s) has/have the right to inspect the manufacturing premises of Tenderers, before accepting the rate quoted by them or before releasing any purchase order(s) or at any point of time during the continuance of tender and also has the right to reject the tender or terminate/cancel the purchase orders issued and/or not to place further order, based on adverse reports brought out during such inspections. Copy of one full set of the documents submitted for the bid should be made available at the time of inspection.

B) Originals of all the documents uploaded/submitted in the Technical Bids should be produced for verification during Site inspection and Physical Verification.

15. ACCEPTANCE /REJECTION OF BIDS:

A) BPPI reserves the right to accept or reject the tender for the supply of all or any one or more items of the drugs tendered for in a tender without assigning any reason.

B) Evaluation of the tender and determination of the L1 rate (Lowest rate) will be done based on rate per unit size exclusive of GST as mentioned in column 7 of **BOQ.** BPPI shall have the right to call other eligible bidders those are willing to match L1 rates. If such firms are found, then the order quantity may be dispersed in ratio of: -

"Minimum 30% quantity to L1 bidder and remaining among the bidder's subject to the matching of L1 price for quoted drugs at the discretion of BPPI".
Purchase preference shall be given to the bidders having manufacturing units approved by foreign accreditation i.e., US FDA. TG Australia, Health Canada, EU approval, MCC South Africa approval, Brazil Anvisa.

C) However, in case the price quoted by the lowest responsive tenderer (L1) is not reasonable and un-acceptable, the price may be negotiated with L1 only as per CVC guidelines and, if it reduces the price to the desirable level, rate contract may be concluded with L1. To meet the demand, BPPI shall conclude parallel rate contract by counter offering the L1 rate to higher eligible bidders as per above provision.

D) Negotiation if required will be done strictly as per Central Vigilance Commission guidelines.

E) Letter of acceptance of tenders for Rate Contract will be communicated to the Tenderers in writing as per **ANNEXURE XI.**

16. AWARD OF CONTRACT:

A) The contract will be awarded to the lowest evaluated responsive bidder qualifying to the final round after Technical and Price Bid evaluation as per the clause 5. B) Determination of L1 bidder and clause 16. B. Acceptance /Rejection of BID, subject to the reservations and preferences to BPPI.

"Minimum 30% quantity to L1 bidder and remaining among the bidder's subject to the matching of L1 price for quoted drugs at the discretion of BPPI".
Purchase preference shall be given to the bidders having manufacturing units approved by foreign accreditation i.e., US FDA. TG Australia, Health Canada, EU approval, MCC South Africa approval, Brazil Anvisa.

B) Letter of Acceptance:

The Tender Inviting Authority shall issue Letter of Acceptance (LOA) as per Annexure-XI to the lowest responsive bidder in respect of the drugs selected. Communication by e-mail / fax / letter will be deemed as valid communication.

C) The successful bidder, upon receipt of the Letter of Acceptance (LOA), shall communicate the acceptance of the same to the BPPI and shall furnish the documents, asked if any.

D) The bidder shall not, at any time, assign, sub-let or make over the contract or the benefit thereof or any part thereof to any person or persons whatsoever. Such practices will be deemed as fraudulent practices and also as breach of terms of contract and shall invite punitive action.

17. PERFORMANCE SECURITY DEPOSIT:

A) On being informed about the acceptance of the tender for Rate Contract, the Performance Security Deposit @ 3% will be deducted from each running bills and accumulated security deposit will be refunded without any interest by BPPI to the tenderer within 60 days following the date of completion of tenderers performance obligations under the contract including the shelf-life obligation.

B) The Security deposit of supplier will be returned by BPPI only after the supplier has given undertaking to replace such medicines and indemnify BPPI against any losses on account of quality parameters duly notarized.

18. METHODOLOGY FOR PLACING ORDERS:

For the above purpose the following procedures will be adopted

A) After the conclusion of Price Bid opening (Cover B), the rates offered by tenderers for each product are evaluated and lowest acceptable rate (L1 Rate) arrived at is declared and that tenderer is informed**.**

B) **BPPI reserves right to issue purchase order for any drug on any one rate contract holder or more than one rate contract holder for same drugs**.

C) If two or more than two Tenderer's are declared as lowest suppliers for the same item(s), such Tenderers are eligible for Rate Contract and the placement of Purchase Orders for such item(s) for which they are declared as lowest.

D) The supplier shall start supply of the Drugs/Medicines to any or all the Warehouse (Address/Location) **as mentioned in clause 19 (A)** or any other place decided by BPPI and supply shall confirm to the conditions mentioned in the provision of tender documents, viz, logo, nomenclature, specification etc. within the stipulated period.

E) The supplier shall supply the Drugs/Medicines at any of the BPPI Warehouse **as mentioned in purchase order** (or any other place decided by BPPI) along with copy of Purchase order, copy of test reports and 3 original copies of Invoice. No payment will be processed without test reports.

F) A purchase order is placed on supplier for supply of definite quantity in terms of Rate Contract during validity period of Rate Contract that purchase order is valid and binding contract.

G) No Minimum drawl is in the Rate Contract. The actual quantity may vary from nil to maximum required quantity during validity of Rate Contract.

H) The Drugs/Medicines supplied in excess of the ordered quantity shall not be accepted and the supplier shall take back the excess at their cost. BPPI will not be responsible for the loss to the supplier and will not entertain any demand/claim.

I) The purchaser reserves the right to conclude one or more than one rate contract for the same item.

J) The purchaser has the option to renegotiate the price with the rate contract holders. In case of emergency, the purchaser may purchase the same item through Ad hoc contract with a new supplier.

K) Purchase orders, incorporating definite quantity of drugs/products to be supplied along with all other required conditions following the rate contract terms, shall be issued for obtaining supplies through the rate contract.

L) The purchaser is entitled to place purchase orders up to the last day of the validity of the rate contract and, though supplies against such purchase orders will be affected beyond the validity period of the rate contract, all such supplies will be guided by the terms & conditions of the rate contract.

M) The details of the required drugs, medicines, etc. are shown in ANNEXURE -XII. *The tender quantity mentioned herein is not a fixed procurement quantity and it is only a tentative requirement and may be increased or decreased* by the BPPI, at its discretion, depending on it is actual need.

Though the tentative quantity is indicated in the Rate Contract, the BPPI, will confirm the actual requirement through purchase order/orders from time to time. The tenderers shall supply the drugs only on the basis of the purchase order issued time to time within validity of Rate contract period by the BPPI. Any supply without a valid purchase order will not be acceptable by BPPI and the BPPI shall not be responsible for any loss on this account.

N) However, once the purchase order/orders is/are issued by the BPPI, the tenderer shall not renege from the commitment of supplying the quantity mentioned in the acceptance of tender for Rate Contract.

O) The rates quoted shall not be varied with the Purchase order quantity during the full contract period.

P) The rates quoted and accepted will be binding on the Tenderer for the full contract period of two years and any increase in the price will not be entertained till the completion of this contract period. Accordingly, this clause will be applicable for all orders placed during the contract period. However, Rate Contract validity period may be extended for period up to further one year at same rate, terms & conditions with the consent of the supplier.

Q) No Tenderer shall be allowed at any time and on any ground, whatsoever it may be, to claim revision or modification in the rates quoted by them. Representation to make correction in the tender documents on the ground of Clerical error, typographical error, etc., committed by the Tenderers in the Bids shall not be entertained after submission of the tenders. Cross Conditions such as "SUBJECT TO AVAILABILITY", "SUPPLIES WILL BE MADE AS AND WHEN SUPPLIES ARE RECEIVED" etc., will not be entertained under any circumstances and the tenders of those who have mentioned such conditions shall be treated as incomplete and accordingly the Tender will be summarily rejected.

R) Supplies should be made directly by the tenderer and not through any other Agency / Dealer / Distributors.

S) The supplier shall take utmost care in supplying the quality Drugs/Medicines and ensure that the batch number mentioned in the packages of the Drugs/Medicines tally with the batch number mentioned in the Invoice produced to BPPI for payment. Also, the supplier shall ensure the quantity relevant to the Batch Number of the Drugs/Medicines is mentioned in the invoice. Drugs to be supplied of any batch shall not be accepted with different MRP.

T) "MRP inclusive of all taxes" is to be printed on each unit/label. MRP will be intimated to successful bidders at the time of placing purchase orders.

U) The Rate Contract (RC) awarded under the present tender enquiry will be in the nature of standing offer. Purchase Order (PO) may be placed from time to time against Rate Contract (RC).

V) FALL CLAUSE:

If at any time during the execution of the contract, the controlled price becomes lower or the supplier reduces the sale price or sells or offers to sell such stores, as are covered under the contract, to any person / organization including the purchaser or any department of Central government/state Govt. or its procurement agencies at a price lower than the price chargeable under the contract, he shall forthwith notify such reduction or sale or offer of sale to the purchaser and the price payable under the contract for the stores supplied after the date of coming into force of such reduction or sale or offer of sale shall stand correspondingly reduced

NOTE: BPPI don't give any guarantee of minimum purchase under this Rate Contract.

19. SUPPLY CONDITIONS:

A) Purchase orders will be issued to the Tenderer(s) at the discretion of the BPPI as per actual requirements. All the supplies shall be received at any or all of the following warehouse of BPPI or any other place decided by BPPI:

i) Central Warehouse Gurugram (Bureau of Pharma Public Sector Undertaking of India (BPPI)
Sugal Logistic Park, Warehouse No.1, Opp. GITM College, Bilaspur-Tauru Road

Village Bilaspur and Khasra No. 60//14/2, 17,24,6,15, 16, 25, 7/1, 14/1, 61//9, 10, 11,62//3/2, 4,10//17, 24, 19//3, 8/2, 9/1/1, 12/2/2/2 min 13/1/1 min.
Pin Code – 122413
Phone No. – 011-49431800

ii) **Regional Warehouse Guwahati (Bureau of Pharma Public Sector Undertaking of India (BPPI)**
DAG No. 884 of K P PATTA No. 04, Mughuapara, Pamohi Village, Dist. Kamrup (M) Guwahati, Assam India 781035.
Phone No. – 011-49431800

iii) **Regional Warehouse Chennai (Bureau of Pharma Public Sector Undertaking of India (BPPI)**
79, KIZHMUTHALAMPEDU, PANAPAKKAM,
City Tiruvallur, State Tamil Nadu
Pin Code – 601201
Phone No. – 011-49431800

B) Within 3 days from the receipt of purchase orders the Tenderer should inform BPPI through **BPPI vendor portal** the confirmation for the receipt of the purchase order.

C) The Tenderer should also fill the details of supply/delivery schedule to BPPI through **BPPI vendor portal** within 7 days from the receipt of the purchase order with expected dispatch/supply date.

i. The bidder shall have to fill Advance supply notice (ASN) on **BPPI vendor portal** with all other details i.e., invoice copy, Certificate of Analysis (COA), Batch no. Quantity, Date of Manufacturing (DOM) Date of Expiry (DOE), no. of shipper boxes etc.

ii. Once the ASN is accepted by the BPPI, the bidder will be provided the date to execute the supplies at BPPI warehouse as mentioned in purchase order.

Note:

- In case, the supply shall not be made by the date as conveyed by the supplier, supply order shall be cancelled at their risk and cost. If no response is received through **BPPI vendor portal** within 7 days from the supplier / tenderer about supply of drugs as per purchase order, it shall be presumed that the supplier/tenderer is not interested to supply the drugs ordered as per purchase order and BPPI shall purchase the drugs from alternative sources.
- In case of newly awarded bidder, bidder must share their permanent email ID and phone number for **BPPI vendor portal registration** to it1@janaushadhi.gov.in.

D) The supplier must supply the ordered quantity as follow delivery schedule:

Sl. No.	Nature of Product	Delivery Schedule (Days)
1	Delivery Schedule against first P.O. for injectable/Infusion/Vials (Products required sterility testing)	60 days
2	Delivery Schedule against subsequent P.O. for Injectable/Infusion/Vials (Products required sterility testing)	45 days
3	Delivery Schedule against first P.O. for all drugs except Injectable/Infusion/Vials (Products do not required sterility testing)	45 days
4	Delivery Schedule against subsequent P.O. for all drugs except Injectable/Infusion/Vials (Products do not required sterility testing)	45 days
5	For biological products	60 days
6	Vaccines and Blood products	120 Days

E) If the delivery date happened to be a holiday for BPPI, the supply should be completed by 5.00 PM on the next working day.

F) In case of Non- execution of the order, BPPI reserves the right to place purchase orders (partially/fully) on alternate source at the risk and cost of the default tenderer(s) without any notice/Information.

G) If a supplier fails to execute supply as per Purchase Order, the 5% of value of unexecuted quantity of Purchase Order shall be recovered from pending bill/Bank Guarantee/Performance security deposit and their bad performance shall be kept in record of BPPI for future dealing as considered appropriate by BPPI.

H) If the Tenderer fails to execute the supply within the stipulated time, the BPPI is at liberty to make alternative arrangement for purchase of the items for which the Purchase orders have been placed, from any other sources or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the defaulted supplier and in such cases the BPPI has every right to recover the cost and impose Liquidated Damages as mentioned in Clause 25.

I) The liquidated damages as specified in clause 25. (B) of the tender conditions will be levied on the quantity supplied after the schedule as mentions in "Clause 19. (D) from the date of issue of purchase order. However, no supplies will be accepted after 30 days of the expiry of delivery date i.e., completion of specified liquidated damages period as per clause 25 (B), the purchase order shall be cancelled at the risk and cost of the supplier. **However, the supplier must take prior approval from BPPI for supply of drugs beyond stipulated delivery period in Purchase order.**

J) Supplier shall complete the earliest pending purchase order before commencing the supply of subsequent purchase orders. **Further, supplies against a purchase order are to be made in minimum numbers of batches as far as possible and same batch should not be supplied in repeated consignment.**

K) Bidder must comply to the shelf life of each quoted drugs in accordance with **Schedule P of Drugs and Cosmetics Rules, 1945. In case drug/medicine not covered in Schedule P of Drugs and Cosmetics Rules, 1945, the bidder must supply the drug/medicine with minimum 24 months shelf life. Bidders must declare the required shelf-life detail in Para VI of Annexure II.**

L) The Tenderer must submit an Analysis report for every batch of drug along with invoice. In case of failure on part of the supplier to furnish such report, the batch of drugs will be returned to the suppliers and he is bound to replenish the same with Govt. approved lab test report. The Drugs supplied by the successful Tenderer shall be of the best quality and shall comply with IP/BP/USP and the specifications, stipulations and conditions specified in the tender.

M) Tenderer should supply the product as follow:

(i) Within 2 months excluding month of manufacture of products having shelf life up to 2 years,
(ii) Within 3 months excluding month of manufacture of products having shelf life more than 2 years & up to 3 years and
(iii) Within 4 months excluding month of manufacture of products having shelf life more than 3 years
(iv) Within 3.5 months excluding month of manufacture of products for drug code 574 HUMAN RABIES VACCINE INJECTION 2.5 IU.

Products supplied beyond the above-mentioned period from the date of manufacturing shall levied a LD as Per Clause 25. (E) of tender documents. For example, product having manufacturing of November 2020 must be supplied by 31st January 2021 in case shelf life up to 2 Years.

N) If at any time the Tenderer has, in the opinion of the BPPI delayed the supply of drugs due to one or more reasons related to **Force Majeure events** such as riots, mutinies, wars, fire, storm, tempest or other exceptional events at the manufacturing premises, the time for supplying the drugs may be extended by the BPPI at discretion for such period as may be considered reasonable. However, such extension shall be considered only if a specific written request is made by the

Tenderer within 10 days from the date of occurrence of such event with necessary documentary evidence. The supplier shall not be liable to pay LD and forfeiture of Security deposit for the delay in executing the contract on account of the extension of supply period on the ground of force majeure events.

O) The exceptional events do not include the Scarcity of raw material, Increase in the cost of raw material, Electricity failure, Labour disputes/Strikes, Insolvency, and Closure of the Factory/Manufacturing unit on any grounds etc.

P) Suppliers are required to supply the drugs within the delivery period mentioned in the purchase order. In this regard it is informed to the bidders that their performance shall be considered unsatisfactory in case of delayed supply (beyond delivery period) or non-supply of products. BPPI may reject their bid in future tenders considering their unsatisfactory performance of supplies.

Q) Leaked, soiled, broken containers with damaged labels shall not be accepted.

R) If BPPI observes some physical defects (like empty blisters, improper labelling) of the supplies during sampling, the batch shall be rejected. If supplier wants to take back the batch for rectification, they can take back at their cost, rectify and send back to BPPI within 15 days otherwise same batch shall not be accepted. Due to rectification, if its shelf-life condition as per tender provision does not meet, it shall be discretion of BPPI depending upon requirement to accept the goods with penalty.

S) Tenderers shall not supply the drugs declared banned by Government of India, even if Purchase Order is placed.

20. LOGOGRAM:

Logogram means, wherever the context occurs, the design as specified in **Enclosure 1 & 2 of ANNEXURE-VII. The name of the drug shall be mentioned in English and Hindi** as per pharmacopoeia and its strength.

A) Tenders should supply for Drugs etc., as per the specifications such as name, strength, minimum size and packed with appropriate size of the strips/blisters/bottles/tubes etc. as per the design enclosed as per **Enclosure 1 to ANNEXURE –VII** and **Enclosure 2 to ANNEXURE –VII.**

B) All dosage form has to be supplied in packing as specified in product list (**ANNEXURE XII**) and shall also conform to Schedule P1 of the Drugs & Cosmetics Act & Rules 1945, wherever it applies. Affixing of stickers and rubber stamps shall not be accepted and supplies will be returned back at supplier's cost.

C) Vials, Ampoules (more or equal than 5 ml) and Bottles containing the items tendered for should also carry the printed PMBJP logogram of proportionate size.

D) Failure to supply Drugs etc., with the printed logogram of proportionate size will be treated as breach of the terms of Rate Contract / violation of tender conditions. The purchase order shall be cancelled at the risk and cost of the supplier. However, if such failure continuous despite notice, will be viewed as a serious lapse and initiate blacklisting of the supplier and levied a LD as per clause 25 (D) of tender documents.

E) Drugs without GS-1 Standard Barcoding on Primary, Secondary and Tertiary Packaging will not be accepted.

21. PACKING:

A) The drugs shall be supplied in the package specified in **ANNEXURE -VIII** and **ANNEXURE - XII** and the package shall carry the logograms of proportionate size specified in 1 to **ANNEXURE –VII & 2 to ANNEXURE –VII** and shall also conform to Schedule P1 of the Drug & Cosmetic Act & Rules 1945, whether it applicable.

Non-affixing of logograms will be treated as violation of tender conditions and fine will be deducted from the amount payable as per condition in Clause 25 (D) of tender documents.

B) The drugs in any dosage form to be supplied by the supplier should not be embossed indicating any code no./logo or name of the company. Failure to comply with this shall lead to non-acceptance of the goods besides imposition of penalties as per clause 25. (D)

C) The packing in each carton shall be strictly as per the specification mentioned in **Annexure-VIII**. The outer carton/secondary packaging should be of pearl white duplex board (**off white/grey is not acceptable**) with a minimum of 350 GSM with **Gloss laminated** packing for the strips, blisters, ointments, creams etc. and for ampoules and vials should be with pearl white board of 350 GSM (**off white/grey is not acceptable**)**. The material to be used for carton should be from virgin chemical pulp.** Failure to comply with this shall lead to non-acceptance of the goods besides imposition of penalties as per clause 25 (D). Storage conditions must be indicated on outer label.

D) **The** cap of bottle preparations should not carry the name/logo/other details of the supplier. However, cap may contain BPPI logogram.

E) The labels in the case of Injectable preparations should clearly indicate whether the preparations are meant for Intravenous (IV), Intramuscular (IM), Intra Dermal (ID), Subcutaneous (SC) administration etc.

F) It should be ensured that only virgin packaging material of uniform size, including bottle and vial, is used for packing.

G) All primary packing containers should be strictly conforming to the specification included in the relevant pharmacopoeia.

H) **Packing** should be able to prevent damage or deterioration during transit.

I) The packings/labels of two different products of a same supplier should be clearly distinct from each other

J) In the event of items of drug supplied found to be **not as per specifications in respect of their packing and logogram**, the BPPI is at liberty to make alternative purchase of the items of drugs for which the Purchase orders have been placed from any other sources or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the supplier. In such cases the BPPI has every right to recover the cost and impose penalty as mentioned in Clause 25 & 26.

K) Designs of packaging with the logograms shall be subject to approval by BPPI within 3 days of receipt of purchase order or within 30 days of release of letter of acceptance. Text matter of all type of label must be checked and responsibility shall be of manufacturer.

In case of failure of BPPI to do so, the supplier may go ahead with the design as per the specification in Enclosure-1 to ANNEXURE VII and Enclosure-2 to ANNEXURE VII.
STP (Standard Testing Procedure) for Non- Pharmacopoeia awarded drugs are required to submit within 15 days from the date of Letter of Acceptance.

L) **The colour of the strength must be different from the colour of the generic name of the drug on primary and secondary packaging and the approval for the same should be taken from the quality/regulatory department while taking artwork approval. The printing ink used should be of good quality (clarity, brightness, contrast) which is easily readable.**

M) **WHO-GMP certified, Therapeutic code & NABL lab tested shall be indicated on the primary and secondary packaging and shall be incorporated as per the approval from the quality/regulatory department while taking artwork approval.**

N) **Barcodes as per GS-1 standards are required to be printed on products at various packaging levels (Primary, Secondary and Tertiary) as per Annexure-IX.**

22. QUALITY TESTING & QUALITY CONTROL:

A. All the batches of the drugs supplied shall be supported by test/ analysis reports furnished by independent NABL Accredited Drugs Testing Laboratory/Central Drug Testing Laboratory/In House Quality Control Laboratory. The Tender Inviting Authority has the right to get the drugs tested at the laboratories of his choice for further verifications, from BPPI empanelled laboratories.

B. Random samples of each supplied batch will be chosen at the point of supply or distribution/storage points for testing. The samples will be sent to different BPPI empanelled laboratories including Government Drugs Testing Laboratory/NIPER/PSU labs for testing. Handling and testing charges will be deducted by BPPI for the above purpose, as specified in Clause 24.

C. **STP (Standard Testing Procedure) for Non- Pharmacopoeia awarded drugs are required to submit within 15 days from the date of Letter of Acceptance by mail to Quality and Regulatory officer of BPPI with artwork approval for design of packaging with the logogram as per Clause 21.K.**

D. The Drugs shall have the active ingredients at the prescribed level as indicated in official compendiums throughout the shelf-life period of the drug. The samples will be drawn periodically throughout the shelf-life period and if found "Not of Standard Quality", the cost of entire batch paid will be recovered whether consumed fully/partially. Also, action will be initiated for blacklisting as per clause 26 irrespective of the period of supply. The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories. Samples which do not meet quality requirement shall render the relevant batches liable to be rejected. If the sample is declared to be "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected goods.

E. In the event of the samples of Drugs supplied fails in quality tests or found to be not as per specifications, the BPPI is at liberty to make alternative purchase of the items of drugs for which the Purchase orders have been placed from any other sources or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the supplier and in such cases the BPPI has every right to recover the cost and impose penalty as mentioned in Clause 26(I).

F. If the product / sample fails in quality test, every failed batch shall be taken back by the supplier at their own cost and BPPI shall not be responsible for any damage during this period.

G. The supplier shall furnish evidence of the basis for shelf life and other stability data concerning the commercial final package on request by the BPPI. In case of any complaint in the field, the B.M.R/ B.P.R for the particular batch of the product(s) supplied shall be produced when demanded. **For New drugs, complete stability data of 6 months' period shall be acceptable.**

H. **The** products should conform to the standards of IP/BP/USP/EP/JP as the case may be. **However, the drugs notified in the IP (amended up to date) shall be accepted only if supplied conforming to the standards outlined in the IP.** In case the product is not included in the any of the said compendiums, the supplier, upon award of the contract, must provide the reference standards and testing protocols for quality control testing.

I. The case of admixture of drugs will be treated as a violation of tender conditions and fine will be levied as per clause 26. If such lapses happen more than twice in a tender period such cases will be treated as "Misbranded Drugs".

23. PAYMENT PROVISION:

A) No advance payments towards costs of drugs will be made to the supplier.

B) Payments towards the supply of drugs will be made within 60 days from the date of receipt of goods, strictly as per the tender terms and condition. The payment will be made either by means of a/c payee Cheque or through RTGS (Real Time Gross Settlement System)/Core Banking/NEFT. The Tenderer shall furnish the relevant details in original **(ANNEXURE -V)** to make the payment through RTGS/Core Banking/NEFT.

C) All bills/Invoices should be raised in triplicate and the bills should be drawn as per GST Rules in the name of Bureau of Pharma Public Sector Undertakings of India. 8th Floor, Videocon Tower, Block-E1, Jhandewalan Extension, New Delhi-110055 or in the name of any other authority as may be designated.

D) (i) Payments for supply will be considered only after supply of minimum 50% of Drugs ordered in the individual Purchase Order PROVIDED reports of Standard Quality on samples testing are received from Government Analyst or Approved Laboratories of BPPI.

(ii) However, in case of cancellation of a particular purchase order due to failure in delivery, payment for part supplies less than 50% of the purchase order quantity on the date of cancellation of the purchase order may be considered for release of payment subject to the following:

a) If the Tenderer have supplied at least 50% of the quantity ordered in the subsequent purchase order within delivery period stipulated in purchase order from the issue of such purchase order.
b) If further purchase order is not placed with the supplier due to any reason, not attributable to the supplier, the amount eligible will be paid within 60 days from the date of last supply.
c) The payment for part supply as mentioned above will subject to the deduction of liquidated damages, penalty towards unexecuted quantity, risk, and cost etc., as per the tender conditions.

E) If at any time during the period of contract, the price of tendered items is reduced or brought down by any law or Act of the Central or State Government or by the Tenderer himself, the Tenderer shall be bound to inform the BPPI immediately about such reduction in the contracted prices. Tender Inviting Authority is empowered to unilaterally effect such reduction as is necessary in rates in case the Tenderer fails to notify or fails to agree for such reduction of rates.

F) In case of any increase of decrease in the Taxes/GST after the date of submission of tenders and during the tender period, such variation in the taxes/GST will be to the account of the BPPI. For claiming the additional cost on account of the increase in taxes/GST, the Tenderer should produce the proof of having paid additional amount on this account on the goods supplied to BPPI from the concerned authorities and also must claim the same in the invoice separately. However, the basic price structure and the price of the Drugs approved under the tender shall not be altered. Similarly, if there is any reduction in the taxes/GST and statutory levies as notified by the Govt., after the date of submission of tender, the Tenderer will be paid based on the unit rate worked out on the basis of the reduced taxes/GST/statutory levies without any change in the basic price or the price structure of the drugs approved under the tender. Any increase or decrease in taxes/GST and statutory levies will be considered based on the notification issued by the Government.

G) However, if the firm supplies after originally stipulated Delivery period, increase in taxes/GST due to statutory variation in taxes/GST shall be borne by the supplier. In case of decrease in taxes/GST due to statutory variation in taxes/GST, the same shall be passed on by the supplier to the BPPI.

24. HANDLING & TESTING CHARGES:

In all supplies, 1.5% of the supply value shall be deducted towards handling & testing charges.

25. LIQIDATED DAMAGES & OTHER PENALTIES:

A) All supply should be made within the stipulated time as per the clause 19.D of the Delivery Schedule and quantity as mentioned in the Purchase Order.

B) If the supply reaches the Drug Warehouses beyond the stipulated time as mentioned in PO/Bid document, liquidated damages will be levied at the rates 2% per week or part thereof, subject to maximum of 10% irrespective of the fact that whether the BPPI has suffered any damage/loss or not, on account of delay in effecting supply

C) If the supply is received in damaged condition it shall not be accepted. The supplier shall have to replace the goods with damage and the penalty equal to the penalty for unexecuted supplies will be levied for the damaged goods and payments will be withheld till proper replacement.

D) All the Tenderers are required to supply the product(s) with printed MRP as per purchase order and logogram of appropriate size on the strips, blisters, vials, ampoules& bottles and with prescribed packing specification. If there are any deviation in these Tender conditions, action will be taken to blacklist the product, and/or a separate damage will be levied @ 5% of value of the defaulted quantity irrespective of the Tender Inviting Authority having actually suffered any damage/loss or not, without prejudice the rights of alternative purchase specified in Clause No.19F,19 H and 21.J.

E) If supplier supplied the drug time beyond the manufacturing date as mentioned in clause 19. (M) of supply conditions, a liquidation damage will be levied @ 5% per month subject to maximum 30% (Up to 6 months).

F) In all the above conditions, the decision of the Tender Inviting Authority shall be final and binding.

26. DEDUCTION & OTHER PENALTIES ON ACCOUNT OF QUALITY FAILURE:

A) If the samples do not conform to statutory standards, the Tenderer will be liable for relevant action under the existing laws and the entire stock in such batch has to be taken back by the Tenderer within a period of 30 days of the issue of the letter from the BPPI. Such stock shall be taken back at the expense of the Tenderer. Further, actual handling and testing charges shall be paid to BPPI by the supplier otherwise these charges shall be recovered from their pending bill/Performance Security Deposit.

B) The BPPI has the right to destroy such "NOT OF STANDARD QUALITY DRUGS" if the Tenderer does not take back the goods within the stipulated time. The BPPI will arrange to destroy the "NOT OF STANDARD QUALITY DRUGS" after the expiry of 30 days mentioned above without further notice and shall also collect handling charges (in case the product is sent back to supplier on freight to pay basis)/ demurrage charges calculated at the rate of 2% per week on the value of the drugs rejected till such time stipulated. Further, the cost of disposal shall be recovered from the supplier.

C) If any items of Drugs/Medicines supplied by the Tenderer have been partially or wholly used or consumed after supply and are subsequently found to be in bad odour, unsound, inferior in quality or description (Adulterated/Spurious/Misbranded) or otherwise faulty or unfit for consumption, then the contract price or prices of total such batches supplied will be recovered from the Tenderer, if payment had already been made to him. In other words, the Tenderer will not be entitled to any payment whatsoever for Items of drugs found to be of "NOT OF STANDARD QUALITY" whether consumed or not consumed and the Tender Inviting Authority is entitled to

deduct the cost of such batch of drugs from any amount payable to the Tenderer. On the basis of the nature of failure, action will be initiated to blacklist the product/supplier.

D) For the supply of Adulterated/Spurious/Misbranded, as defined in the Drugs and Cosmetics Act, 1940, to BPPI. BPPI reserves the right to blacklist the supplier. No further supplies shall be accepted from the firm/company.

If the tenderer is blacklisted, the tenderer shall also not be eligible to participate in tenders of Tender Inviting Authority of BPPI for supply of Drugs for a period of 5 years from the date of blacklisting.

In case of supply of NOT OF STANDARD QUALITY drug(s) to BPPI, the product shall be blacklisted by BPPI and no further supplies shall be accepted for the particular drug (s). The Tenderer shall also not be eligible to participate in tenders of BPPI for supply of such Drugs for a period of 2 years from the date of blacklisting.

In addition, the Director of Drugs Control of concerned State will be informed for initiating necessary action on the Tenderer in their state. Performance Security Deposit will also be forfeited without any intimation.

E) The Tenderer shall furnish the source of procurement of raw material utilized in the formulations, if required by the BPPI. The BPPI reserves the right to cancel the purchase orders if the source of supply is not furnished.

F) The decision of the BPPI or any officer authorized by him, as to the quality of the supplied drugs, medicines etc., shall be final and binding. In such cases, the BPPI will be at liberty to terminate, the contract either wholly or in part on 30 days' notice. The Tenderer will not be entitled for any compensation whatsoever in respect of such termination besides forfeiture of Performance Security Deposit.

G) For contravention of the stipulations of the contract or for other justifiable reasons, the contract may be terminated by the BPPI, and the Tenderer shall be liable to pay for all losses sustained by the BPPI in consequence of the termination which may be recovered from the Tenderer, as per rules besides forfeiture of Performance Security Deposit.

H) Non-performance of any of the contract conditions and provisions will disqualify a firm from participating in the tender for the next 2 years/ Blacklisting the tenderer.

I) In the event of making Alternative Purchase, as specified in Clause 19.H, Clause 21.J and in Clause 22.F penalty will be imposed on the supplier. The excess expenditure over and above contracted prices incurred by the BPPI in making such purchases from any other sources or in the open market or from any other Tenderer who has quoted higher rates and other losses sustained in the process, shall be recovered from the Performance Security Deposit or from any other money due and become due to the supplier and in the event of such amount being insufficient, the balance will be recovered personally from the supplier as per rules.

J) In all the above conditions, the decision of the BPPI shall be final and binding.

27. BLACKLISTING IN THE EVENT OF WITHDRAWAL FROM THE TENDER, AND NON-ADHERENCE TO THE QUALITY STANDARDS AND SUPPLY SCHEDULE:

A) BLACKLISTING OF PRODUCT/TENDERER ON WITHDRAWAL OF TENDER

If the Tenderer fails to perform the obligations under the tender conditions / commits default in the performance of the contract/LOA, such Tenderers will be blacklisted for a period of **2 years** by BPPI from the date of intimation besides forfeiture of Performance security deposit.

The Tenderers who have withdrawn after participating in the tender after the last date and time of submission of online bid, either fully or partially, **the entire firm/company** will be blacklisted for

a period of **2 years** from the date of intimation by BPPI apart from forfeiture of the Security Deposit.

B) **BLACKLISTING FOR QUALITY FAILURE/QUALITY TEST BY THE EMPANELLED LABORATORIES OF BPPI.**

a) Each and every batch of drugs/medicines supplied by the supplier shall be subjected to quality test by the Empaneled laboratories as per the procedure adopted by BPPI.
BPPI shall also draw the samples of products supplied in the marketplace and get the same tested, to make sure the products are conforming to quality requirements till Self life.

b) If the sample of any batch fails in quality test and report is received stating "Not of standard quality "in any test the report along with the chromatograms etc. such batch of drugs shall be rejected & no further procurement of that drug from the supplier will be taken for two years from the date of sample being declared not of standard quality.

(i) If the supplier challenges and request for retesting, the sample shall be tested at government testing laboratory or reputed govt. institute like NIPER. The test report of govt. lab or NIPER will be final and will be binding to the supplier.
(ii) The cost of such Re-testing shall be recovered from the supplier.
(iii) If **2** batches of item/drug supplied by the same supplier is reported to NOT OF STANDARD QUALITY in specification, then the firm shall be blacklisted for 2 years after observing procedure laid down in Para 27.B.(d) besides forfeiture of Performance Security Deposit.
(iv) If a single batch of any product(s) supplied by the company/firm declared as Adulterated/spurious/ Misbranded by the Government Authorities during the shelf life of the product supplied irrespective of tender period, the company/firm shall be blacklisted for a period of **2 years from the date of intimation & forfeiture of security deposit.**

C) Quality Test by Statutory Authorities:

(i) If any drug is declared "NOT OF STANDARD QUALITY", by any government agencies or drug licensing authority, the issue of available stock of the particular item will be stopped. Further, the available stock of the product in hospitals/JAS will be retrieved.
(ii) If any batch of any product(s) supplied by the company/firm declared, NOT OF STANDARD QUALITY in specification as defined in the Drugs and Cosmetics Act, 1940, by the Government Authorities during the relevant tender period or during quality check within shelf-life period, the company/firm shall be blacklisted for a period of 2 **years from the date of blacklisting** after observing procedure laid down in Para 27.B(d)

D) Procedure for Blacklisting:

(i) On receipt of complaint from Distributer/retailers/customers or report from Govt. Analyst/Drug Testing Laboratory indicating that a particular Item/Drug is "**NOT OF STANDARD QUALITY/ ADULTERATED/ SPURIOUS/MISBRANDED" (**As the case may be), a show cause notice shall be issued to the supplier calling for explanation within 7 days from the date of notice. On receipt of explanation from the supplier, the CEO, BPPI may take appropriate action on merits of the case and impose penalty including the blacklisting of the item of the product/company or firm as deemed fit besides forfeiture of Performance Security Deposit.
(ii) If a particular item of the drug has been blacklisted according to the procedure stated above, the supplier is not eligible to participate in any of the tenders for such item floated by the BPPI until the period of blacklisting is over.

(iii) If a supplier company/firm is blacklisted according to the procedure stated above, such supplier is not eligible to participate in any of the tenders floated by the BPPI until the period of blacklisting is over.

E) BLACKLISTING FOR NON-SUPPLY:

Due to non-supply of item against any purchase order, 5 % value of purchase order shall be recovered from the supplier in addition of other penal like risk purchase.
In case of repeated circumstances of non-supply of items i.e., 2 times, the supplier may be blacklisted for 2 years in addition of forfeiture of Performance Security Deposit and other penal action.

28. SAVING CLAUSE:

No suit, prosecution or any legal proceedings shall lie against the Tender Inviting Authority or any person for anything that is done in good faith or intended to be done in pursuance of the tender.

29. RESOLUTION OF DISPUTES

The BPPI and the supplier shall make every effort to resolve, amicably by direct informal negotiation any disagreement or dispute arising between them under or in connection with the contract.

A) ARBITRATION AND JURISDICTION.

Normally, there should not be any scope of dispute between the BPPI and the supplier after entering a mutually agreed valid contract/ Rate Contract.
However, due to various unforeseen reasons, problems may arise during the progress of the contract/ Rate Contract leading to disagreement BPPI and the supplier shall first try to resolve the same amicably by mutual Consultation. If the parties fail to resolve the dispute by such mutual consultation within twenty-one days, then, depending on the position of the case, either the BPPI or the supplier shall give notice to other party of its intension to commence Arbitration procedure as per Indian Arbitration and Conciliation Act, 1996. Such disputes/differences shall be referred to Sole Arbitrator to be appointed by the CEO of BPPI. The venue of Arbitration Shall be at New Delhi. The award published by the Arbitrator shall be final and binding on the parties.

30. CONTACTING THE BPPI BY THE BIDDER:

A) No bidder shall contact the BPPI on any matter relating to its bid, from the time of bid opening to the time the contract is awarded.

B) Any effort by a bidder to influence the BPPI in the Purchaser's bid evaluation, bid comparison or contract award decisions may result in rejection of the bidder's bid.

C) The bidder shall not make any attempt to establish unsolicited and unauthorized contact with the Tender Accepting Authority, Tender Inviting Authority or Tender Scrutiny Committee after opening of the bids and prior to the notification of award and any attempt by any bidder to bring to bear extraneous pressures on the Tender Accepting Authority, Inviting Authority or Tender Scrutiny Committee, shall be sufficient reason to disqualify the bidder.

D) Notwithstanding anything contained in clause (C) above the Tender Inviting Authority or the Tender Accepting Authority, may seek bonafide clarifications from bidders relating to the bids submitted by them during the evaluation of bids.

31. FRAUDULENT AND CORRUPT PRACTICES:

A) For Bidders:

It is purchaser's policy to ensure that suppliers and their authorized representatives/agents observe the highest standard of ethics during the procurement and execution of such contracts. (In this context, any action taken by a bidder, supplier, contractor, or by their authorized representatives/agent, to influence the procurement process or contract execution for undue advantage is improper) In pursuance of this policy, the purchaser.

a) Defines, for the purposes of this provision, the terms set forth below as follows:

(i) "corrupt practice" is the offering, giving, receiving, or soliciting, directly or indirectly, of anything of value to influence improperly the actions of another party ("another party" refers to a public official acting in relation to the procurement process or contract execution]. In this context, "public official" includes staff and employees of other organizations taking or reviewing procurement decisions.

(ii) "fraudulent practice" is any act or omission, including a misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, a party to obtain a financial or other benefit or to avoid an obligation (a "party" refers to a public official; the terms "benefit" and "obligation" relate to the procurement process or contract execution; and the "act or omission" is intended to influence the procurement process or contract execution).

(iii) "collusive practice" is an arrangement between two or more parties designed to achieve an improper purpose, including to influence improperly the actions of another party ["parties" refers to participants in the procurement process (including public officials) attempting to establish bid prices at artificial, non-competitive level].

(iv) "coercive practice" is impairing or harming, or threatening to impair or harm, directly or indirectly, any party or the property of the party to influence improperly the actions of a party (a "party" refers to a participant in the procurement process or contract execution).

(v) "obstructive practice" is (a) deliberately destroying, falsifying, altering or concealing of evidence material to the investigation or making false statements to investigators in order to materially impede a investigation into allegations of a corrupt, fraudulent, coercive or collusive practice; and/or threatening, harassing or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the investigation or from pursuing the investigation; or acts intended to materially impede the exercise of the purchaser's inspection and audit rights provided for under sub-clause (e) below.

b) Will reject a proposal for award if it determines that the bidder considered for award has, directly or through an agent, engaged in corrupt, fraudulent, collusive, coercive, or obstructive practices in competing for the contract in question.

c) will cancel the contract if the purchaser determines at any time that the bidder, supplier and contractors and their sub-contractors engaged in corrupt, fraudulent, collusive, or coercive practices

d) will sanction a firm or individual, including declaring in eligible, either indefinitely or for a stated period of time, to be awarded a contract if it at any time determines that the firm has, directly or through an agent, engaged in corrupt, fraudulent, collusive, coercive or obstructive practices in competing for, or in executing, a contract; and

e) will have the right to inspect the accounts and records of the bidders, supplier, and contractors and their subcontractors/authorized representatives and to have them audited by auditors appointed by the purchaser.

B) For Suppliers:

If the BPPI determines that a Supplier has engaged in corrupt, fraudulent, collusive, coercive or obstructive practices, in competing for or in executing the Contract, then the BPPI may, after giving 7 days' notice to the Supplier, terminate the Supplier's engagement under the Contract and cancel the contract, and the procurement will be made at the risk and cost of the supplier besides blacklisting the bidder for 5 years with forfeiture of Performance Security Deposit apart from other penal actions.

a) For the purposes of this Sub-Clause:

(i) "corrupt practice" is the offering, giving, receiving, or soliciting, directly or indirectly, of anything of value to influence improperly the actions of another party.

(ii) "fraudulent practice" is any act or omission, including a misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, a party to obtain a financial or other benefit or to avoid an obligation.

(iii) "collusive practice" is an arrangement between two or more parties designed to achieve an improper purpose, including to influence improperly the actions of another party.

(iv) "coercive practice" is impairing or harming, or threatening to impair or harm, directly or indirectly, any party or the property of the party to influence improperly the actions of a party.

(v) "obstructive practice" is (aa) deliberately destroying, falsifying, altering or concealing of evidence material to the investigation or making false statements to investigators in order to materially impede a purchaser investigation into allegations of a corrupt, fraudulent, coercive or collusive practice; and/or threatening, harassing or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the investigation or from pursuing the investigation; or (bb)acts intended to materially impede the exercise of the purchaser's inspection and audit rights provided for.

32. JURISDICTION:

In the event of any dispute arising out of the tender such dispute would subject to the jurisdiction of the Civil Court within the city of Delhi only.

…….

ANNEXURE – I

Ref. Clause 3 (N)

CHECK-LIST (Whether Uploaded the documents)

COVER – A

S.N.	Check List	YES /No	Page No.	Remarks
1	Check list – ANNEXURE – I **as per clause 3. N.**			
2	Bid Security declaration on non-judicial stamp paper as per **ANNEXURE-III (Clause 3. A & 6. A)**.			
3	NSIC or MSME certificate (If claimed for EMD exemption) as per Clause No. 3. A Note.			
4	Copies of documentary evidence for the constitutions of the company / Firm/ Proprietorship such as Memorandum and Article of Association, Partnership deed with complete address as per Clause 3. B.			
5	Power of attorney or Resolution of board by which the authorized signatory has been authorized by the Tenderer to sign the tender documents as per clause 3. C.			
6	Copy of Minimum three years old valid Manufacturing License of the product quoted with latest license renewal certificate as per Clause 3. D.			
7	Copy of Market Standing Certificate issued by the Licensing Authority from Drug Controller Administration of the State for minimum 2 batches in last 3 Years as per Clause no. 3. E.			
8	Copy of Non-Conviction Certificate issued by the concerned Licensing Authority from Drug Controller Administration of the State, not older than 12 months as per Clause no. 3.F.			
9	Copies of **WHO-GMP** (WHO-Good Manufacturing Practice) as per revised Schedule- 'M'/COPP Certificate of the manufacturing unit issued by the Licensing Authority/ Drugs Control Department/FDA. The WHO-GMP certificate must not be older than one year from the last date of submission of tender as per Clause 3. G.			
10	Copy of Maximum Production Capacity Certificate (section wise) issued by concerned Licensing Authority Form Drugs Control Department/FDA highlighting the quoted product section as per Clause no. 3.H..			
11	ANNEXURE –II (Declaration **On non-judicial Stamp Paper** for eligibility in participating the tender) **original Annexure II delivered to BPPI as per clause 3. J.**			
12	ANNEXURE-V **(Mandate form) to furnish company bank details as per clause 3 (K) & 23(B)**			
13	ANNEXURE-VI indicating manufacturing License, validity of license and market standing certificate details **as per clause 3. L.**			
14	ANNEXURE-VII (Declaration to supply the drugs as per the design in enclosure 1 and enclosure 2 in Annexure VII) as per clause 3(M) , 20 & 21			
15	Copies of **approval of Manufacturing Unit of the any agency like** US FDA, TG Australia, Health Canada, EU, MCC South Africa approval, Brazil Anvisa, **if any as per clause 3 (S).**			
16	Copy of valid GS-1 registration certificate for bar coding as per Clause 3. R.			

17	Copy of Audited Annual Balance sheet and Profit and loss statement showing details of their Annual average turn over not less than 25 crores for any three of the last four consecutive financial years as per Clause 3. I**.**			
18	ANNEXURE IV {certificate from the C.A. (Chartered Accountant) or Company Secretary. **Original Annexure IV delivered to BPPI as per clause 3. I.**			
19	Self-attested copy of PAN Card of the Bidder Company. As per Clause 3(O).			
20	Self-attested copy of Certificate of valid GST registration of the bidder company. As per Clause 3(P).			
21	Self-attested copy of Income Tax Return for any three of last four consecutive Assessment years. As per Clause 3(Q).			
22	Authorization letter nominating an employee of the tenderer to transact the business with the Tender Inviting Authority as per clause 4. P.			

NOTE: - Bid Security Declaration (ANNEXURE III), ANNEXURE II, ANNEXURE IV, ANNEXURE V and ANNEXURE VI are to be delivered in original to BPPI, rest of the document duly authorized should be submitted on or before stipulate date as mentioned in the tender document "technical cover A".

Name of authorized signatory: …….

Signature of authorized signatory: …….

Company seal:

ANNEXURE –II

(On nonjudicial Stamp Paper)

Ref. Clause No. 3.(J)

DECLARATION

I/We M/s. ……..represented by its Proprietor/Managing Partner /Managing Director having its registered office at …….....and its factory premises at……..……..…… ……do hereby declare as under: -

(I) that I/we have carefully read all the terms and conditions of tender in ref. no**. BPPI/DRUG/RC-159/2021 dated 13/01/2021** including Amendment(s) to Tender document (if any) issued by Bureau of pharma public sector undertakings of INDIA, New Delhi,110055 and accept unconditionally all terms and condition of tender document including Amendment(s) to Tender document (if any).

(II) **A**. that I/We are holding and have uploaded (a) valid drug license for quoted drugs,(b) valid WHO-GMP certificate , (c) 3 years market standing certificate for quoted products issued by licensing authority, (d) a certificate manufactured & marketed two batches within 3 years issued by C.A. for quoted drugs, (e) valid non conviction certificate not older than 12 months,(f) declaration of the active API polymorphic form used in formulation for quoted drugs and declare that it is internationally accepted active polymorph **(if any)** and (h) the copies of the specifications for all quoted drugs and STP (standard testing procedure) for Non- Pharmacopoeia quoted drugs and also enclosed all undertaking/declaration as per Annexure mentioned in the tender document.

(II) B. that I/We shall submit the complete stability data (long term stability studies and accelerated stability studies) for all awarded drugs within 15 days from the date of issue Letter of Acceptance. (If manufacturer has licensed a formula from another company and such licensed formula is used for the product, then the stability data of the licensor shall be submitted along with licensing agreement.)

(II) C. that I/we shall supply the drugs as per specification, composition, strength, design, logo and packing given in ANNEXURE-XIII and Shape, Colour, Packing Type, etc. of drugs shall be as given in ANNEXURE-XIV

On the basis of above undertaking/declaration, the price bid shall be opened subsequently after opening of technical bid. However, any document uploaded with technical bid is not complying as per undertaking, the contract/ Rate Contract shall be cancelled with forfeiture Performance Security Deposit/Bank guarantee (if any) against tender no. BPPI/DRUG/RC-159/2021 dated **13/01/2021** along with other action including suspension/disqualification of contract**.**

(III) a.) I/We declare that we possess the valid drug manufacturing license for BPPI's tendered items as per details below:

Sr. No.	Drug Code	Description of Drug as per BPPI Tender	Unit Size	Drug Lic. No.	Date of Issue	Validity of Drug Lic.	Address of Manufacturing Unit

b.) I/We declare that we possess the valid WHO-GMP (World Health Organization-Good Manufacturing Practices) Certificate issued by competent authority and complies and continue to comply with the condition lied in schedule M of Drug & cosmetic act, 1940 the rules made there under.

I am / We are aware of the Tender inviting Authority's right to forfeit the Performance Security Deposit and suspending/disqualifying/blacklist me/us for a period of 5 years if, any information furnished by us proved to be false at time the of inspection and not complying the condition as per schedule M of the said Act for a period of five years.

(IV)

(a) I do hereby declare that I have uploaded valid GS1 registration certificate for bar coding and will supply the drug with bar code as per ANNEXURE IX and as per the design as per enclosures to ANNEXURE XII enclosed with tender document as well as other instruction given in this regard.

(b) We have valid approval of the any agency like US FDA, TG Australia, Health Canada, EU, MCC South Africa approval, Brazil Anvisa, (if any) only for following quoted drugs and relevant certificate & approval indicating/highlighting drug code have been uploaded with technical bid: -

S. No.	Drug Code	Description of Drug as per BPPI Tender	Unit Size	Whether approval of the any agency like US FDA, TG Australia, Health Canada, EU, MCC South Africa approval, Brazil Anvisa (yes/No)

(V) that in pursuant to the conditions in Clause No. 6. (A) of the tender, the bids can be suspended/disqualified by the Tender Inviting Authority in case of violation of any of the conditions and non-performance of the obligation under tender document.

(VI) that our company/applied items have not been blacklisted/debarred/de-registered/banned **due to quality failure for the quoted product /firm by any State Government / Central Government/ BPPI/ Central or State Government's Drug procurement agencies** for the following products quoted in the tender at the time of submission of bid. Further, quoted drugs have not been failed in house testing or testing by any State Government/Central Government / its Drug procurement agencies/BPPI during last two years. We are eligible to participate in the tender ref. No. **BPPI/DRUG/RC-159/2021 dated 13/01/2021** for the following quoted products with mentioned shelf life in Annexure XIII: -

S. No.	Drug Code	Description of Drug as per BPPI Tender	Unit Size	Shelf life complying the Schedule-P" of the Drugs and Cosmetics Rule, 1945.

Signed.....

Name: ……..

Designation…….…….

(Company Seal)

Witness: -

(1) Signed: …….

Name: .....

Designation: …….

(2) Signed: …….

Name: .....

Designation: …….

To be attested by the Notary

ANNEXURE –III

Ref. Clause No. 3(A), 6. (A)

DETAILS OF BID SECURITY DECLARATION SUBMITTED

Upload the scanned copy of bid security declaration as per the format in Annexure – X

Note: *(i) The Micro and Small enterprises (MSEs) and the firms registered with National Small Industries Corporation (NSIC) etc. are exempted from submitting the Bid Security as per prevailing rules. However, they have to submit the valid documentary evidence in support of MSE/Registration with NSIC (indicating the items for which they are registered.) along with the technical bid.*

(ii) PSU's are exempted from the submission of Bid Security Declaration.

ANNEXURE- IV

Ref. Clause No. 3. (I)

{Format for a certificate from the C.A. (Chartered Accountant) or Company Secretary}

(I) It is certified that M/s.....……is a Private Ltd./Ltd. /Proprietorship/Partnership company/firm and they have PAN no…….and GST registration no……..……..They have filed Income tax returned and GST returned up to date. The authorized signatory of the company/firm is Shri…….and whose signature is attested as under:……..

(II) The annual Turnover of M/s. ..... for any three of the last four consecutive financial years for manufacturing of drugs are given below and certified that the statement is true and correct.

Sl. No.	Financial Year	Turnover in Rupees (₹) in Crore (Rs.)	Turnover in Rupees in Crore (in words)
1.	2016-17	₹	
2.	2017-18	₹	
3.	2018-19	₹	
4.	2019-20	₹	
Total Turnover		Rs (₹)..... Crore	Rs (in words)……..
Average Turnover per annual		Rs (₹)..... Crore	Rs (in words)……..

It is certified that M/S …….(Name of company and address)having factory at…… (address of factory) have required plant/plants, machinery/machineries, building/buildings & other infrastructure to manufacture the tendered drugs. It is also certified that the statement is true and correct.

(III) It is certified that M/s _____ has Production & financial
capacity to manufacture and deliver the drugs quoted by them in the tender as per quantity & delivery schedule mentioned in tender. This certificate is based on their Manufacturing capacity, inventory of raw Material and financial statement.

(IV) Further, It is certified that M/S ……is Micro and Small Enterprises (MSE) and registered with Director of Industries of concerned State/UT or appropriate authorities for quoted drugs against BPPI tender No. **BPPI/DRUG/RC-159/2021** and eligible for exemption of submission of Bid Security Declaration. This MSEs is owned by Scheduled Caste (SC)/Scheduled Tribe (ST) entrepreneurs.

(V) They have manufactured & marketed 2 or more commercial batches of each quoted drugs in last three years.

Note: Turnover certificate (Annexure-IV) shall be submitted in original on CA/CS letter head.

Date: Name: ……

Signature: ……..

Stamp: ……

Registration No.:…….

NOTE

(i) Strike which is not applicable in above certificate.

(ii) MSEs would be treated as owned by SC/ ST entrepreneurs: a) In case of proprietary MSE, proprietor(s) shall be SC /ST b) In case of partnership MSE, the SC/ST partners shall be holding at least 51% (fifty-one percent) shares in the unit c) In case of Private Limited Companies, at least 51% (fifty-one percent) share shall be held by SC/ST promoters.

ANNEXURE V

Ref. clause 3 (K) & 23. (B)

MANDATE FORM

Sl. No.	Details Required	
1.	**Company Name**	
2.	Postal Address of the Company	
	GST No.	
	Telephone No.	
	Fax No.	
	E-mail ID	
3.	Name of the Managing Director / Director / Manager	
	Mobile No. / Phone No	
	E-mail ID	
4.	Name and Designation of the authorized company official	Name:
		Designation:
	Mobile No.	
	E-mail ID	
5.	**For Vendor Portal Registration**	
	Permanent E-mail ID	
	Permanent Mobile No.	
6.	**Bank Details**	
	a) Name of the Bank	
	b) Branch Name & address	
	c) Branch Code No.	
	d) Branch Manager Mobile No.	
	e) Branch Telephone no	
	f) Branch E-mail ID	
	g) 9-digit MICR code number of the bank and branch appearing on the MICR cheque issued by the bank	
	h) IFSC Code of the Branch	
	i) Type of Account (Current / Savings)	
	j) Account Number (as appear in cheque book)	

(In lieu of the bank certificate to be obtained, please **attach the original cancelled cheque** issued by your bank for verification of the above particulars).

I / We hereby declare that the particulars given above are correct and complete. If the transaction is delayed or not effected at all the reasons of incomplete or incorrect information, I would not hold Bureau of Pharma Public Sector Undertakings of India (BPPI) responsible. I have read the conditions of the tender / Rate contract entered and agree to discharge the responsibility expected of me / from the company as a tenderer / successful tenderer.

Date: Signature :

Name :

Designation:

Place: Company Seal (Name of the person signing & designation)

CERTIFIED THAT THE PARTICULARS FURNISHED ABOVE BY THE COMPANY ARE CORRECT AS PER OUR RECORDS.

Signature of the authorized official of the bank

Bank Seal with address:

Annexure VI

Additional Document

Tender No. BPPI/DRUG/RC-159/2021

Ref Clause No. 3 (L) **Date:**

S. N.	Drug Code (Only Quoted Drugs as mentioned in Annexure II)	Drug Specification (As per Tender Specification)	Unit Size	Drug Manufacturing License					Marketing standing Certificate (MSC)		
				Drug Manufacturing License No.	License Issue date	License Renewal Date	License Validity Date	Page no. of Document in uploaded Scan Copy (Do not put page nos. in range)	Market Standing Certificate Issue Date	Period of Marketing as per Marketing standing Certificate (MSC)	Page no. of Document in uploaded Scan Copy (Do not put page nos. in range)

Note:

(i) In case any details as desired above is missing/not submitted against quoted drugs, the bid for such drugs are liable to be rejected.

(ii) It is strictly do not put page nos. in range, indicate the page nos. one by one for all respective quoted drugs codes.

Signature:

Name:

Authorized Signatory:

Seal of the Company:

ANNEXURE -VII

Ref. Clause no 20 & 21

DECLARATION

I/We do hereby declare that I/we will supply the drug as per the design in Enclosure 1 to Annexure VII & Enclosure 1 to Annexure VII as well as other instruction given in this regard.

Signature of the Tenderer

Name: ……

Designation: ……..

(Company Seal)

Enclosure–1 to ANNEXURE - VII

Ref. Clause No. 20

DESIGN FOR: Foil / blister of tablet and capsule

1. **Text Matter Printing on** Foil /Blister should be in minimum two colour i.e. Black & red.
   However, colour and design of PMBJP (Pradhan Mantri Bhartiya Janaushadhi Pariyojana) logogram in standard colour format & BPPI Drug code-XXXX as given in PO as per approval at the time of ART WORK approval before supply should be as given below.

2. PMBJP Logogram should be placed along with the address as given below.
3. BPPI helpline number 1800 180 8080 should be printed.

4. Font type should in CALIBIRI format for any type of title name of generic medicines.

5. Title name of generic medicine should be **bold** in minimum 12 font size & the strength corresponding to it must be **bold** in minimum 14 font sizes and it may increase respectively according to size of label & the rest text matter should be in minimum 8 font size.
6. The stereo printing of batch no./manufacturing /expiry date & other details shouldn't overlap the text matter.

7. "Bureau of Pharma PSUs of India" should be running text only and should not be prominent.

1. Pradhan Mantri Bharitya Janaushadhi Priyojana should be printed in Hindi at side of strips.

Enclosure – 2 to ANNEXURE – VII
Ref. Clause No. 20

1. **Design for injection for primary packing**

a) Vial (5ml or more) should be supplied with the following PMBJP logogram **& BPPI Drug code-XXXX as given in PO as per approval at the time of ART WORK approval before supply** as under:

b) BPPI helpline number 1800 180 8080 should be printed

c) Font type should in CALIBIRI format for any type of title name of generic medicines

d) Title name of generic medicine should be minimum 12 font sizes and it may increase respectively according to size of label.

e) "Bureau of Pharma PSUs of India" should be running text only and should not be prominent.

Manufactured for:

प्रधानमंत्री भारतीय जन औषधि परियोजना

Bureau of Pharma PSUs of India
8th Floor, Videocon Tower, Block-E1, Jhandewalan Extension, New Delhi-110055
BPPI helpline number 1800 180 8080 BPPI DRUG CODE—XXXX

b) Ampoules or Vials less than 5 ml for primary packing

(i) Injection in ampoule or vial (less than 5 ml) should be supplied with PMBJP logogram **& BPPI Drug code-XXXX as given in PO as per approval at the time of ARTWORK approval before supply**.

(ii) BPPI helpline number 1800 180 8080 should be printed.

(i) Font type should in CALIBIRI format for any type of title name of generic medicines.

(ii) Title name of generic medicine should be minimum 12 font sizes and it may increase respectively according to size of label.

(iii)"Bureau of Pharma PSUs of India" should be running text only and should not be prominent.

Manufactured for:

प्रधानमंत्री भारतीय जन औषधि परियोजना

Bureau of Pharma PSUs of India
8th Floor, Videocon Tower, Block-E1, Jhandewalan Extension, New Delhi-110055
BPPI helpline number 1800 180 8080 BPPI DRUG CODE—XXXX

(ii) LIQUID:

a) Liquid preparation should be supply with pilfer proof ROPP cap.

b) Bottle cap should not bear the manufacturer's logogram

c) Bottle label should bear PMBJP logogram **& BPPI Drug code-XXXX as given in PO as per approval at the time of ARTWORK approval before supply** as below:

d) BPPI helpline number 1800 180 8080 should be printed

e) "Bureau of Pharma PSUs of India" should be running text only and should not be prominent

f) Font type should in CALIBIRI format for any type of title name of generic medicines

g) Title name of generic medicine should be minimum 12 font sizes and it may increase respectively according to size of label.

Manufactured for :

प्रधानमंत्री भारतीय जन औषधि परियोजना

Bureau of Pharma PSUs of India
8th Floor, Videocon Tower, Block-E1, Jhandewalan Extension, New Delhi-110055
BPPI helpline number 1800 180 8080 BPPI DRUG CODE--XXXX

OINTMENTS / CREAMS

a) Ointment / Cream /Gel /Glass Jar should bear PMBJP logogram **& BPPI Drug code-XXXX as given in PO as per approval at the time of ART WORK approval before supply** as below:

Manufactured for :

प्रधानमंत्री भारतीय जन औषधि परियोजना

Bureau of Pharma PSUs of India
8th Floor, Videocon Tower, Block-E1, Jhandewalan Extension, New Delhi-110055
BPPI helpline number 1800 180 8080 BPPI DRUG CODE—XXXX

b) BPPI helpline number 1800 180 8080 should be printed

c) Ointment / cream tube should be packed in mono carton (secondary packing) with PMBJP logogram **& BPPI Drug code-XXXX as given in PO as per approval at the time of ART WORK approval before supply** as given below.

d) "Bureau of Pharma PSUs of India" should be running text only and should not be prominent

e) Font type should in CALIBIRI format for any type of title name of generic medicines

f) Title name of generic medicine should be minimum 12 font sizes and it may increase respectively according to size of label.

ANNEXURE-VIII

Ref. Clause No. 21

SCHEDULE FOR PACKAGING OF DRUGS

GENERAL SPECIFICATIONS

1. Strips of Aluminium foils should be 0.07 mm thickness and grammage of foil minimum 80 g/m^2, LDPE minimum 35 g/m^2 and total GSM not less than 110 g/m^2.
2. Aluminium foils back material for blisters should be minimum 0.025 mm thickness, grammage of foil minimum 75 g/m^2 and tensile strength minimum 400 Kg/cm^2.
3. The rigid PVC used in blister packing should be of not less than 250 microns (thickness) and grammage minimum 350 g/m^2.
4. ALU-ALU blisters, total grammage minimum 250 g/m^2, total minimum thickness 130 microns, and bursting strength minimum 15 Kg/cm^2.
5. Pin hole should be nil and toxicity should be comply as per USP in all foil and PVC.
6. All glass bottles should be new neutral glass, Type-1, free from visual defects.
7. Pet bottles used for syrups/solution should be clean, standard for market and so accepted as per drug laws stipulation.
8. Ointments should be packed in lacquer zed Aluminium Tubes or Lami tubes and properly sealed.
9. Small Tablets packed in blisters should be packed to facilitate easy removal of the tablet without breaking / crushing.
10. Specification of outer cartons should be as per given in their Schedule.
11. In case of any conflict between Carton specifications and packets per carton specification the specification of the packets / carton shall prevail.
12. All plastic containers should be made of virgin grade plastics
13. Injection in vials should have a flip-off seals.
14. Container used for infusions should be as per market standard and must not leak during use.
15. The strips shall be aluminium strip / blisters with aluminium foil back.
16. The outer carton/secondary packaging should be of pearl white duplex board (**off white/grey is not acceptable**) with a minimum of 350 GSM with **Gloss laminated** packing for the strips, blisters, ointments, creams etc. and for ampoules and vials should be with pearl white board of 350 GSM (**off white/grey is not acceptable**)**. The material to be used for carton should be from virgin chemical pulp.**

17. All liquid oral preparations to be provided with a measuring plastic cup, fitted over the cap of the bottle in a mono carton. In case of Paediatric Preparation, all liquid oral has to be provided with a measuring plastic cup, dropper fitted over the cap of the bottle in a mono carton.

18. All primary/secondary/tertiary packaging should have PMBJP logo and drug code mentioned as per purchase order.

16. Two Horizontal/vertical/standing lines in two different colour will be there on Primary and secondary packaging, to differentiate therapy groups. The colours of lines will be intimated during Artwork approval.

The primary packing should be decided by the party depending on the drug category as per Drug & Cosmetic act. For e.g if drug is hygroscopic then tablet should be packed in Alu/Alu blister or if it is light sensitive then to be packed in Amber colour PVC e.t.c.

Shipper size or corrugated box specification with weights

S. N	Particulars	Weight	Ply	Grammage	Bursting strength
1	Tablets	Not more than 12.0 Kg	7	Outer box should be 150 GSM and inside partition/ lining should be 120 GSM.	Not less than 10 Kg/cm^2.
2	Capsules (Hard gel and soft gel)	Not more than 12.0 Kg	7		
3	Syrups	Not more than 12 to14.0 Kg	7		
4	Ointment/gel/cream	Not more than 12.0 Kg	7		
5	Injection (vial, respules and ampules)	Not more than 8-12.0 Kg	7		
6	IV fluids	Not more than 12.0 Kg	7		
7	Bottles/Jars	Not more than 12.0 Kg	7		

(4) In the case of 10 ml Ampoules, 20 or 25 ampoules may be packed in a mono carton. Multiples of mono carton boxes should be packed in CB.

(5) If the vial is packed in individual carton, there is no necessity for grey board box packing. The individual carton may be packed as such in the CB with center pad.

(6) In case of ampoules less than 10 ml, every 10 or 5 ampules should be inside the tray with printed white board box.

(7) Vials of eye, ear drops, and nasal drops should be packed in an individual mono carton with a dispensing device. If the vial is of FFS/BFS technology, they should be packed as per approved artwork and market standard.

ANNEXURE IX
(BARCODE REQUIREMENTS}

Reference clause 3(R)

GS1 barcode requirements on Drugs procured by Bureau of Pharma Public Sector undertakings of India (BPPI)

These requirements cover medicines/drugs procured by Bureau of Pharma Public Sector Undertakings of India (BPPI), New Delhi meant for supply and distribution through BPPI regulated distribution channel.

Barcode based on GS1 identification standards are provided below at various levels of product packaging which includes primary, secondary and shipper/carton levels and need to be complied with while supplying medicines/drugs to BPPI.

GS1 India is unique identification & barcoding standards body setup by Ministry of Commerce & Industry, Govt. of India along with APEDA, BIS, Spices board, IIP and apex industry chambers like CII, FICCI, ASSOCHAM to assist India industry and govt. bodies on adoption of global standards.

Suppliers are also required to provide GS1 subscription validity certificate at the time of supply of medicines/drugs issued by GS1 India. For validity certificate suppliers can contact GS1 India at 011-42890-846.

Barcodes based on GS1 global standards are required to be printed on product packaging at primary, secondary and tertiary packaging levels **in addition** to other, existing statutory labelling & marking requirements.

Tertiary Level Pack:

Is defined as a level of packaging that shall contain one or more secondary/primary levels of packaging and is also considered as the final logistics unit like shippers/pallets.

The Tertiary label will carry two barcodes in GS1-128 format

First Barcode

a) *Unique product identification code (GTIN - Global Trade Identification Number)*
b) *Manufacturing Date*
c) *Expiry date*
d) *Batch no.*
e) *Quantity*

Second Barcode

f) *Serial Shipping Container Code (SSCC) –*

Note-

1) *While encoding Manufacturing and expiry date in the barcode, if a specific Manufacturing or expiry date is not printed on the finished pack/drug then Supplier should select first day of the month as the Manufacturing date and Last day of the month as expiry date.*

   Example- If Shelf life is 24 months, April 2019 manufacturing date should be encoded as 190401 and March 2021 expiry date as 210331.

2) *SSCC number of the Tertiary pack should never be reused on another Tertiary pack irrespective the Item, Batch or expiry is different.*

3) *For converting, GTIN-13 into GTIN-14, kindly use "0" as a prefix for all levels of packaging.*

Attribute	Description	Length	Nature	Data Type
(02)	*Application Identifier to indicate GTIN-14 Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
0 8901072 00253 3	*Unique Product Number-GTIN-14*	*14*	*Fixed*	*Numeric*
(11)	*Application Identifier to indicate Manufacturing date Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
180101	*Expiry Date in YYMMDD format*	*6*	*Fixed*	*Date*
(17)	*Application Identifier to indicate Expiry date Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
220131	*Expiry Date in YYMMDD format*	*6*	*Fixed*	*Date*

(10)	*Application identifier to indicate Lot/batch number Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
BATCH123	*Batch No / Lot No*	*20*	*Variable*	*Alphanumeric*
(37)	*Application identifier to indicate Quantity in Outer Carton*	*2*	*Fixed*	*Numeric*
500	No of Primary packs like number of strips/Bottles in the tertiary.	*Upto 8*	*Variable*	*Numeric*
(00)	*Application identifier to indicate the SSCC Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
1 8901072 000000000 6	*Unique number of the tertiary pack. It should never be reused.*	*18*	*Fixed*	*Numeric*
Recommended Barcode – GS-128				

Secondary Level Pack:

Is defined as a level of packaging that may contain one or more primary packages usually termed as Mono-carton/carton

Secondary level barcode can be generated using 2D- GS1 Datamatrix or 1D- GS1-128 format.

Note-

1) Shrink wrap packaging will not be considered as Secondary level packaging.
2) *For converting, GTIN-13 into GTIN-14, kindly use "0" as a prefix for all levels of packaging.*

Data Attributes Captured in GS1 Datamatrix format

1) *Unique product identification code (GTIN)*

2) *Batch No.*
3) *Qty- No of strips/bottle*

Attribute	Description	Length	Nature	Data Type
(02)	*Application Identifier to indicate GTIN-14. Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
0 8901072 00253 3	*GTIN-14- Unique product code with first digit being the packaging indicator*	*14*	*Fixed*	*Numeric*
(10)	*Application identifier to indicate Lot/batch Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
BATCH123	*Batch No / Lot No*	*Upto 20*	*Variable*	*Alphanumeric*
(37)	*Application Identifier to indicate serial number Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
5	*Quantity/Units in Secondary pack*	*Upto 8*	*Variable*	*Alphanumeric*
Recommended Barcode depending upon the space available – GS1 Data matrix Or *GS1-128*	 (02) 0 8901072 00255 3 (10) BATCH123 (37) 5 *or*  (02) 0 8901072 00255 3 (10) BATCH123 (37) 5			

Primary Level Pack:

Is defined as the first level of packaging in direct contact with the product like Strip, Vial, Bottle etc

<u>Scenario-I</u> Primary pack with a Mono-carton/Carton/Secondary level pack

For primary packaging packed in a Mono-carton/Secondary pack carton

Unique product identification code (GTIN)

Note-

- *For converting, GTIN-13 into GTIN-14, kindly use "0" as a prefix for all levels of packaging.*

Attribute	Description	Length	Nature	Data Type
(01)	*Application Identifier to indicate GTIN-14 Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
0 8901072 00253 3	*GTIN-14 with first digit being the packaging indicator*	*14*	*Fixed*	*Numeric*
Recommended Barcode – GS1 Datamatrix,	 (01) 0 8901072 00255 3			

<u>Scenario-II</u> Primary pack without Mono-carton/Secondary level pack

For Primary packaging going directly into Tertiary pack without a Carton/Mono-carton/Secondary pack

- *Unique product identification code (GTIN)*
- *Batch No.*

Note-

- *For converting, GTIN-13 into GTIN-14, kindly use "0" as a prefix for all levels of packaging.*

(01)08901072002533
(10)BATCH123

Attribute	Description	Length	Nature	Data Type
(01)	*Application Identifier to indicate GTIN-14. Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
0 8901072 00253 3	*GTIN-14- Unique product code with first digit being the packaging indicator*	*14*	*Fixed*	*Numeric*
(10)	*Application identifier to indicate Lot/batch Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
BATCH123	*Batch No / Lot No*	*Upto 20*	*Variable*	*Alphanumeric*

Mapping of Manufacturer GTIN with BPPI Drug code-

- GS1 has facilitated an online application to link Manufacturer GTIN code with BPPI Drug code. The manufacturer must update the same before sending the physical consignment to BPPI.
- Kindly contact Mr. Ankit Arora or Mr. Amrit Garg for the same at 011-42890846/42890818 or write email at ankit@gs1india.org or amrit@gs1india.org

Barcode Design and Printing-

- For BPPI suppliers, GS1 India has facilitated an online application to generate the barcode designs for each level of packaging.
- Using the same, the supplier will be able to generate Primary, Secondary and Tertiary barcodes as per BPPI format.
- Kindly contact Mr. Ankit Arora or Mr. Amrit Garg for the same at 011-42890846/42890818 or write email at ankit@gs1india.org or amrit@gs1india.org

Please contact GS1 India office for any further assistance –

GS1 India
(Under Min. of Commerce, Govt. of India)
330, 2nd Floor, 'C' Wing, August Kranti Bhawan,
Bhikaji Cama Place, New Delhi - 110066
T +91-11-42890890, (D) +91-11-42890846
F +91-11-26168730
E ankit@gs1india.org
W http://www.gs1india.org

ANNEXURE –X

BID SECURITY DECLARATION

(On nonjudicial Stamp Paper)

Ref. Clause No. 6.(A)

Date : [DD/MM/YYYY]
Tender No.:

To:
[Purchaser]

I/We……., the undersigned, declare that: I/We understand that, according to **Pharma Public Sector Undertaking of India (BPPI)** tender conditions, bids must be supported by a Bid-Securing Declaration.

I/We accept that I/we may be disqualified/ suspended from bidding for any contract with the **Bureau of Pharma Public Sector Undertaking of India (BPPI)** for the period of two (2) years, if I am/we are in a breach of any obligation under the bid conditions, because I/we:

(a) have withdrawn or modified my/our Bid during the period of bid validity specified in the Form of Bid; or

(b) having been notified of the acceptance of our Bid by the **BPPI** during the period of bid validity, (i) fail or refuse to execute the Contract, if required, or (ii) fail or refuse to furnish the Performance Security, in accordance with the Instruction to Bidders.

I/We understand this BID SECURITY DECLARATION shall cease to be valid if I am/we are not the successful Bidder, upon the earlier of (i) the receipt of your notification of the name of the successful Bidder; or (ii) thirty days after the expiration of the validity of my/our Bid.

Signed: [signature of person whose name and capacity are shown] In the capacity of [insert legal capacity of person signing the BID SECURITY DECLARATION]

Name: insert complete name of person signing the BID SECURITY DECLARATION

Duly authorized to sign the bid for and on behalf of: [insert complete name of Bidder]

Dated on _____ day of _____, _____.

Corporate/Company Seal:

Note: In case of a Joint Venture, the BID SECURITY DECLARATION must be in the name of all partners to the Joint Venture that submits the bid.

ANNEXURE-XI

Ref: Clause No. 15.E

Letter of acceptance of tender for Rate Contract

Speed post/e-mail

Ref. No. BPPI/DRUG/RC-159/2021 **Date: …….**

To,
M/S_____
_____

Sub: Tender for the Supply of Drugs and Medicines to BPPI for two years: Acceptance tender for Rate Contract.
Ref: Your quotation against BPPI e-Tender No. BPPI/DRUG/RC-159/2021 dated: 13/01/2021 opened on ……. (Technical Bid) & on …… (Price bid).

Please refer to your quotation i.e. technical and price bid (BOQ) along with enclosures/Annexure against subject tender read with your subsequent clarification/confirmation for the supply of Drugs to BPPI, the rate offered/accepted by your firm has been approved for Rate Contract for two years from the date of issue of this letter.

S. N.	Drug Code	Drug Name	Unit Size	Rates in Rs. Per unit exclusive of GST	Rate of GST(%)	Rates in Rs. Per unit inclusive of GST

2. The contract will be with financial limit and BPPI can place the Purchase Order with unlimited variation in quantities indicated in the tender.
3. The estimated value of the contract awarded to you is Rs.....(in word).
4. Performance Security Deposit @ 3% will be deducted from each bills and accumulated security deposit will be refunded by BPPI to the tenderer within 60 days following the date of completion of tenderers performance obligations under the contract including the shelf-life obligation.
5. Approval for Artwork should be obtained from our Quality Control department by you within 30 days of release of this letter. (e-mail id: procure14@janaushadhi.gov.in; procure12@janaushadhi.gov.in & quality8@janaushadhi.gov.in)
6. STP (Standard Testing Procedure) for Non- Pharmacopoeia awarded drugs are required to submit to Quality Control department (e-mail id: procure14@janaushadhi.gov.in; procure12@janaushadhi.gov.in & quality8@janaushadhi.gov.in) within 15 days from the date of Letter of Acceptance
7. As per clause 4. M of Tender document, the Rate Contract validity period may be extended for period up to further one year at same rate, terms & conditions with the consent of the supplier.
8. The terms and conditions of Rate Contract shall be applicable as mentioned in tender document. By issue of this acceptance letter, the Rate Contract is hereby concluded.

Please acknowledge receipt.

Authorized Signatory,
For and on behalf of BPPI

Annexure -XII
Clause 18 (M)

Bureau of Pharma Public Sector Undertakings of India, New Delhi
Tender for supply of drugs (Tender No. BPPI/DRUG/RC-159/2021 dated-13/01/2021)

(1)	(2)	(3)	(4)	(5)	(6)	(7)
S. No.	**Drug Code**	**Generic Name of the Drug**	**Composition of the Drug**	**Unit Size**	**Pack-size**	**Indicative Requirement in Unit Size**
1	2	Aceclofenac Tablets IP 100 mg	Each film-coated tablets contains: Aceclofenac Tablets IP 100 mg	10's	10's X 10	1800000
2	5	Aspirin Tablets IP 150 mg	Each Gestro-resistant tablets contains: Aspirin IP 150 mg	14's	14's x 10	8000000
3	8	Serratiopeptidase 10mg and Diclofenac Sodium 50mg Tablets	Each Enteric-coated tablets contains: Serratiopeptidase IP 10mg Diclofenac Sodium IP 50mg	10's	10's X 10	1200000
4	10	Diclofenac Sodium Injection IP 25mg per ml	Each ml contains: Diclofenac Sodium IP 25mg	3 ml Ampoule	1's X 10	12000000
5	12	Etoricoxib Tablets IP 120 mg	Each film-coated tablets contains: Etoricoxib IP 120 mg	10's	10's X 10	800000
6	13	Etoricoxib Tablets IP 90 mg	Each film-coated tablets contains: Etoricoxib IP 90 mg	10's	10's X 10	1850000
7	14	Ibuprofen 400mg and Paracetamol 325mg Tablets IP	Each uncoated tablet contains: Ibuprofen IP 400mg Paracetamol IP 325 mg	10's	10's X 10	580000
8	15	Ibuprofen Tablets IP 200 mg	Each Film Coated Tablet contains: Ibuprofen 200 mg	10's	10's X 10	120000
9	16	Ibuprofen Tablets IP 400 mg	Each film-coated tablet contains: Ibuprofen IP 400mg	15's	15's X 10	200000
10	20	Nimesulide Tablets 100 mg	Each Uncoated tablets contains: Nimesulide IP 100mg	10's	10's X 10	1300000
11	21	Diclofenac Sodium 50mg and Paracetamol 325mg Tablets IP	Each uncoated tablet contains: Diclofenac Sodium IP 50mg Paracetamol IP 325 mg	10's	10's X 10	3300000
12	23	Paracetamol Tablets IP 500 mg	Each Uncoated tablets contains: Paracetamol IP 500 mg	10's	10's X 10	12000000
13	25	Serratiopeptidase Tablets IP 10 mg	Each Enteric-coated tablets contains: Serratiopeptidase IP 10 mg	10's	10's X 10	700000
14	38	Amoxycillin 500mg and Potassium Clavulanate 100mg Injection IP	Each vial contains: Amoxycillin Sodium IP equivalent to Amoxycillin 500 mg Potassium Clavulanate IP equivalent to Clavulanic Acid 100 mg	Vial with WFI	1's x 10	110000
15	44	Amoxycillin Capsules IP 250mg	Each Hard Gelatin Capsule contains: Amoxycillin Trihydrate IP Amoxycillin Trihydrate equivalent to Amoxycillin 250mg	10's	10's X 10	1400000
16	45	Amoxycillin Capsules IP 500mg	Each Hard Gelatin Capsule contains: Amoxycillin Trihydrate IP Amoxycillin Trihydrate equivalent to Amoxycillin 500mg	10's	10's X 10	2000000

17	46	Ampicillin Injection IP 500 mg	Each vial contains: Ampicillin Sodium IP (Sterile) equivalent to Anhydrous Ampicillin IP 500mg	Vial with WFI	1's x 10	120000
18	51	Cefadroxil Dispersible Tablets 250mg	Each uncoated dispersible tablet contains: Cefadroxil equivalent to Cefadroxil Anhydrous 250mg	10's	10's X 10	350000
19	55	Cefixime Tablets IP 200 mg	Each film-coated tablets contains: Cefixime IP (As Trihydrate) equivalent to Anhydrous Cefixime 200mg	10's	10's X 10	2850000
20	56	Cefoperazone 1g and Sulbactam 1g Injection	Each vial contains: Cefoperazone Sodium IP (Sterile) equivalent to Cefoperazone 1g Sulbactam Sodium (Sterile) equivalent to Sulbactam 1g	Vial with WFI	1's x 10	100000
21	57	Cefoperazone 500mg and Sulbactam 500mg Injection	Each vial contains: Cefoperazone Sodium IP (Sterile) equivalent to Cefoperazone 500mg Sulbactam Sodium (Sterile) equivalent to Sulbactam 500mg	Vial with WFI	1's x 10	100000
22	59	Cefotaxime Sodium 1g and Sulbactam Sodium 500mg Injection	Each vial contains: Cefotaxime Sodium IP (Sterile) equivalent to Cefotaxime 1g Sulbactam Sodium (Sterile) equivalent to Sulbactam 500mg	Vial with WFI	1's x 10	100000
23	60	Cefotaxime Sodium 250mg and Sulbactam Sodium 125mg Injection	Each vial contains: Cefotaxime Sodium IP (Sterile) equivalent to Cefotaxime 250mg Sulbactam Sodium (Sterile) equivalent to Sulbactam 125mg	Vial with WFI	1's x 10	100000
24	61	Cefotaxime Sodium 500mg and Sulbactam Sodium 250mg Injection	Each vial contains: Cefotaxime Sodium IP (Sterile) equivalent to Cefotaxime 500mg Sulbactam Sodium (Sterile) equivalent to Sulbactam 250mg	Vial with WFI	1's x 10	100000
25	63	Cefotaxime Sodium Injection IP 250 mg	Each ml contains: Cefotaxime Sodium Injection IP equivalent to Cefotaxime IP 250 mg	Vial with WFI	1's x 10	350000
26	68	Ceftazidime Injection IP 250mg	Each Vial contains: Ceftazidime 250 mg	Vial with WFI	1's x 10	100000
27	69	Ceftazidime Injection IP 500mg	Each vial contains: Sterile Mixture of Ceftazidime Pentahydrate IP eq. to Ceftazidime 500 mg	Vial with WFI	1's x 10	100000
28	71	Ceftriaxone 1g and Tazobactam 125mg Injection	Each vial contains: Ceftriaxone Sodium IP equivalent to Ceftriaxone 1000 mg Tazobactam Sodium equivalent to Tazobactam 125 mg	Vial with WFI	1's x 10	150000
29	74	Ceftriaxone 500mg and Sulbactam 250mg	Each vial contains: Ceftriaxone Sodium IP (Sterile)	Vial with WFI	1's x 10	250000

		Injection	equivalent to Ceftriaxone 500 mg Sulbactam Sodium (Sterile) equivalent to Sulbactam 250 mg			
30	75	Ceftriaxone Injection IP 1 g	Each vial contains: Ceftriaxone Sodium IP equivalent to Ceftriaxone 1000 mg	Vial with WFI	1's x 10	2250000
31	76	Ceftriaxone Injection IP 250 mg	Each vial contains: Ceftriaxone Sodium IP equivalent to Ceftriaxone 250 mg	Vial with WFI	1's x 10	100000
32	77	Ceftriaxone injection IP 500 mg	Each vial contains: Ceftriaxone Sodium IP equivalent to Ceftriaxone 500 mg	Vial with WFI	1's x 10	580000
33	78	Cefuroxime Axetil Tablets IP 250 mg	Each film coated tablet contains: Cefuroxime Axetil I.P equivalent to Cefuroxime: 250 mg	10's	10's X 10	530000
34	79	Cefuroxime Axetil Tablets IP 500 mg	Each film coated tablet contains: Cefuroxime Axetil IP equivalent to Cefuroxime 500 mg	10's	10's X 10	690000
35	84	Ciprofloxacin 500mg and Tinidazole 600mg Tablets	Each film-coated tablets contains: Ciprofloxacin Hydrochloride IP equivalent to Ciprofloxacin 500mg Tinidazole IP 600mg	10's	10's X 10	300000
36	86	Ciprofloxacin Hydrochloride Tablets IP 500 mg	Each film-coated tablets contains: Ciprofloxacin Hydrochloride IP equivalent to Ciprofloxacin 500mg	10's	10's X 10	1400000
37	87	Clotrimazole Cream IP 1% w/w	Each gram contains: Clotrimazole IP 1% w/w	15gm tube	1's x 20	2900000
38	90	Co-trimoxazole (Sulphamethoxazole 100mg and Trimethoprim 20mg) Tablets IP	Each uncoated tablet contains: Trimethoprin 20mg Sulphamethoxazole 100mg	10's	10's X 10	110000
39	96	Levofloxacin Tablets IP 500mg	Each Film coated Tablet contains: Levofloxacin Hydrochloride IP equivalent to Levofloxacin	10's	10's X 10	760000
40	97	Meropenem Injection IP 1 g	Each vial contains: Sterile Meropenem IP equivalent to anhydrous Meropenem 1000 mg	Vial with WFI	1's x 10	350000
41	98	Norfloxacin 400mg and Tinidazole 600mg Tablets	Each Film coated Tablet contains: Norfloxacin IP 400mg Tinidazole IP 600mg	10's	10's X 10	700000
42	99	Norfloxacin Tablets IP 400 mg	Each film coated tablet contains: Norfloxacin 400 mg	10's	10's X 10	520000
43	101	Ofloxacin Tablets IP 200mg	Each Film coated Tablet contains: Ofloxacin IP 200mg	10's	10's X 10	1400000
44	102	Ofloxacin Tablets IP 400mg	Each Film coated Tablet contains: Ofloxacin IP 400mg	10's	10's X 10	300000
45	103	Piperacillin 4000mg and Tazobactum 500mg Injection IP	Each vial contains: Piperacillin Sodium IP (Sterile) equivalent to Piperacillin IP 4000 mg Tazobactum Sodium IP equivalent to	Vial with WFI	1's x 10	480000

			Tazobactum IP 500mg			
46	105	Roxithromycin Tablets IP 150 mg	Each Film coated Tablet contains: Roxithromycin IP 150 mg	10's	10's X 10	220000
47	109	Vancomycin Injection IP 500 mg	Each vial contains: Vancomycin Hydrochloride IP equivalent to Vancomycin IP 500 mg	Vial with WFI	1's x 10	100000
48	113	Beclomethasone 0.025%w/w and Neomycin 0.5%w/w Cream	Contains: Beclomethasone 0.025% Neomycin 0.5% w/w	15gm tube	1's x 20	450000
49	117	Chlorhexidine Mouthwash IP 0.2 % w/v	Composition: Chlorhexidine Gluconate Solution IP Diluted to Chlorhexidine Gluconate 0.2 % w/v Pleasantly Flavoured Aqueous Base	100ml Bottle	100 ml X 6	1300000
50	118	Clobetasol Propionate Cream IP 0.05 % w/w	Composition: Clobetasol Propionate IP 0.05 % w/w	15gm tube	1's x 20	1800000
51	125	Povidone Iodine Ointment 5% w/w	Composition: Povidone Iodine IP 5% w/w (available iodine 0.5 % W/W)	15gm tube	1's x 20	2200000
52	131	Silver Sulphadiazine 1% w/w, Chlorhexidine Gluconate 0.2% w/w, Allantoin 0.1% w/w, Aloe vera 15% w/w Cream	Contains: Silver Sulphadiazine 1% w/w, Chlorhexidine Gluconate 0.2% w/w, Allantoin 0.1% w/w, Aloe vera 15% w/w in cream base q.s.	20 gm Tube	1's x 20	190000
53	132	Silver Sulphadiazine 1% w/w, Chlorhexidine Gluconate 0.2% w/w, Allantoin 0.1% w/w, Aloe vera 15% w/w Cream	Contains: Silver Sulphadiazine 1% w/w, Chlorhexidine Gluconate 0.2% w/w, Allantoin 0.1% w/w, Aloe vera 15% w/w in cream base q.s.	500 gm Jar	500 gm x 1	110000
54	135	Gliclazide Tablets IP 40 mg	Each uncoated tablet contains: Gliclazide IP 40 mg	10's	10's X 10	1900000
55	137	Glimepiride Tablets IP 1mg	Each film coated tablet contains: Glimepiride IP 1 mg.	10's	10's X 10	15000000
56	138	Glimepiride Tablets IP 2mg	Each film coated tablet contains: Glimepiride IP 2 mg.	10's	10's X 10	10000000
57	141	Glipizide Tablet IP 5 mg	Each Uncoated tablet contains: Glipizide IP 5 mg.	10's	10's X 10	2950000
58	142	Soluble Insulin Injection IP (Regular) (Recombinant DNA origin)	Each ml contains: Human Insulin IP 40 IU (Human Insulin of recombinant DNA origin) m-cresol 0.25% w/v	10ml Vial	10 ml Vial X10	2900000
59	144	Metformin Hydrochloride Sustained Release Tablets IP 1000 mg	Each film-coated sustained release tablet contains: Metformin Hydrochloride IP 1000mg	10's	10's X 10	27000000
60	153	Cisplatin Injection IP 10 mg per10ml	Each ml contains: Cisplatin 1 mg	Vial	1's x 10	100000
61	156	Doxorubicin Injection	Each ml contains:	Vial	1's x 10	100000

		IP 50mg (2mg/ml)	Doxorubicin Hydrochloride IP 50mg (2mg/ml)			
62	158	Etoposide Injection IP 100 mg per 5 ml	Each ml contains: Etoposide IP 20 mg	Vial	1's x 10	110000
63	181	Cyproheptadine Hydrochloride 2mg and Tricholine Citrate 275mg Syrup per 5ml	Each 5ml contains: Cyproheptadine Hydrochloride IP 2mg Tricholine Citrate 275mg	200 ml Bottle	1's x 10	550000
64	188	Dried Aluminium Hydroxide 250mg, Magnesium Hydroxide 250mg and Activated Dimethicone 50mg Tablets	Each uncoated chewable tablet contains: Dried Aluminium Hydroxide IP 250 mg Magnesium Hydroxide IP 250 mg Activated Dimethicone IP 50 mg	10's	10's X 10	1300000
65	194	Hyoscine Butylbromide Tablets IP 10 mg	Each sugar-coated tablet contains: Hyoscine Butylbromide IP 10 mg	10's	10's X 10	220000
66	195	Ispaghula Husk IP 200gm	Each 100 gm contains: Ispaghula Husk IP 100 g	200gm Tetra-pack	200 gm Tetra-pack X 10	1400000
67	201	Metronidazole Tablets IP 200mg	Each film-coated tablet contains: Metronidazole Tablets IP 200mg Excipients q.s.	10's	10's X 10	900000
68	203	Misoprostol Tablets IP 200 mcg	Each uncoated tablet contains: Misoprostol IP 200 mcg	4's	4's x 10	150000
69	208	Ondansetron Injection IP 2mg per ml	Each ml contains: Ondansetron 2 mg	2ml Ampoule	2ml x 10	1500000
70	216	Ranitidine Injection IP 25 mg per ml	Each ml Contains: Ranitidine Hydrochloride 28 mg IP equivalent to Ranitidine Hydrochloride 25 mg	2ml Ampoules	2ml x 10	2450000
71	224	Folic Acid Tablets IP 5 mg	Each Uncoated tablet contain: Folic Acid IP 5 mg	15's	15's X 10	3850000
72	230	Vitamin B-Complex fort Zinc Capsule	Each hard gelatin capsule contains: Thiamine 10mg Riboflavin 10mg Niacinamide 45mg Pyridoxine Hydrochloride 3mg Cyanocobalamin 15mcg Folic acid 1.5mg Ascorbic acid 150mg Zinc Sulfate Monohydrate 61.8mg (Eq. to 22.5 mg of Elemental Zinc)	10's	10's X 10	7700000
73	231	Vitamin B-Complex Tablets (B1 10mg, B2 10mg, B3 45mg, B5 50mg, B6 3mg, B12 15mcg)	Each film coated tablet contains: Vitamin B1 10mg Vitamin B2 10mg Vitamin B3 45mg Vitamin B5 50mg Vitamin B6 3mg Vitamin B12 15mcg	10's	10's X 10	4500000
74	233	Vitamin-C Chewable Tablets 100mg	Vitamin-C Chewable 100mg Tablet	10's	10's X 10	5300000
75	244	Etofylline 84.7mg and	Each 2 ml contains:	2ml	2ml X 10	1700000

		Theophylline 25.3mg Injection per 2ml	Etofylline 84.7 mg Theophylline anhydrous equivalent to Theophylline hydrate 25.3 mg	Ampoule		
76	246	Fexofenadine Tablets IP 120 mg	Each Film-coated tablet contain: Fexofenadine Hydrochloride IP 120 mg	10's	10's X 10	670000
77	247	Fexofenadine Tablets IP 180 mg	Each Film-coated tablet contain: Fexofenadine Hydrochloride IP 180 mg	10's	10's X 10	680000
78	248	Levocetirizine Tablets IP 5 mg	Each Film-coated tablet contain: Levocetirizine Dihydrochloride IP 5 mg	10's	10's X 10	6100000
79	254	Promethazine Syrup IP 5mg per 5ml	Each 5 ml syrup contains: Promethazine Hydrochloride IP 5mg	100ml Bottle	100 ml X 6	100000
80	255	Salbutamol Inhalation IP 100mcg per puff	Each activation delivers: Salbutamol sulphate IP equivalent to Salbutamol 100mcg	200 md	1's X 10	1300000
81	259	Salbutamol Syrup IP 2mg per 5ml	Each 5 ml contains: Salbutamol Sulphate equivalent to Salbutamol: 2 mg Flavoured Syrup base: q. s.	100ml Bottle	100ml X 10	1600000
82	268	Clonidine Tablets IP 0.1 mg	Each uncoated tablet contains: Clonidine Hydrochloride IP 100mcg	10's	10's X 10	3800000
83	271	Diltiazem Tablets IP 30 mg	Each Film-coated tablet contain: Diltiazem Hydrochloride IP 30 mg	10's	10's X 10	930000
84	273	Dobutamine Hydrochloride Injection IP 250mg per 20ml	Each vial (20ml) contains: Dobutamine 250 mg	Vial	1's x 10	110000
85	276	Enoxaparin Injection IP 40 mg per 0.4 ml	Each prefilled syringe contains: Enoxaparin sodium IP 40mg	0.4 ml Pre-Filled Syringe	1's X 10	210000
86	277	Enoxaparin Injection IP 60 mg per 0.6 ml	Each pre-filled syringe contains: Enoxaparin sodium IP 60 mg equivalent to 6,000 IU anti-Xa activity.	0.6 ml Pre-Filled Syringe	1's X 10	140000
87	278	Frusemide Injection IP 10 mg per ml	Each ml Contains: Frusemide IP 10mg	2ml Ampoules	2ml X 10	1100000
88	279	Frusemide Tablets IP 40 mg	Each Uncoated tablets contains: Frusemide IP 60mg	10's	10's X 10	3200000
89	280	Heparin Sodium Injection IP 1000 IU per ml	Each ml contains: Heparin Sodium IP 1000 IU	5ml Vial	5 ml Vial X10	100000
90	281	Heparin Sodium Injection IP 5000 IU per ml	Each ml contains: Heparin Sodium 5000 IU	5 ml Vial	5 ml X 10	110000
91	283	Isosorbide Dinitrate Tablets IP 10mg	Each uncoated Sublingual tablet contains: Diluted Isosorbide Dinitrate IP 10mg	50's	(50's X 10)	1200000
92	285	Amlodipine 5mg and Lisinopril 5mg Tablets	Each Film coated tablet contains: Amlodipine Besilet IP equivalent to Amlodipine 5mg Lisinopril IP 5mg	15's	15's X 10	300000
93	289	Losartan Tablets IP 50mg	Each Film coated tablet contains: Losartan Potassium IP equivalent to Losartan 50mg	10's	10's X 10	9600000

94	291	Metoprolol Extended-release Tablets IP 50mg	Each film coated extended-release tablet contains: Metoprolol Succinate IP 50mg	10's	10's X 10	12000000
95	302	Tranexamic Acid Injection IP 500 mg (100mg per ml)	Each ml contains: Tranexamic Acid IP 100mg	5 ml Ampoules	5 ml X 10	300000
96	304	α-β Arteether Injection 150 mg	Each 2 ml contains: α-β Arteether 150 mg	2ml Ampoules	2ml X 10	100000
97	305	Chloroquine Phosphate Tablets IP 250 mg	Each film-coated tablet contains: Chloroquine Phosphate IP 250mg	10's	10's X 10	750000
98	311	Disodium Hydrogen Citrate Syrup (Alkalyser) 1.4 gm per 5 ml	Each 5ml contains Di-Sodium Hydrogen Citrate 1.4gm	100 ml	100 ml X 6	950000
99	320	Diazepam Tablets IP 5 mg	Each Film coated tablet contains: Diazepam IP 5mg	10's	10's X 10	400000
100	321	Escitalopram Tablets IP 10 mg	Each Film coated tablet contains: Escitalopram Oxalate IP equivalent to Escitalopram 10mg	10's	10's X 10	1900000
101	323	Flunarizine Tablets 10 mg	Each uncoated tablet contains: Flunarizine Dihydrochloride equivalent to Flunarizine 10mg	10's	10's X 10	450000
102	325	Fluoxetine Hydrochloride Capsules IP 20mg	Each hard gelatin capsule contains: Fluoxetine Hydrochloride IP equivalent to Fluoxetine 20mg	10's	10's X 10	930000
103	327	Phenytoin Tablets IP 100 mg	Each Film coated tablet contains: Phenytoin Sodium IP 100mg	100's in Bottle	1's X 10	1800000
104	328	Prochlorperazine Tablets IP 5 mg	Each Film coated tablet contains: Prochlorperazine Maleate IP 5mg	10's	10's X 10	350000
105	329	Prednisolone Tablets IP 5 mg	Each uncoated dispersible tablet contains: Prednisolone IP 5mg	15's	15's X 10	2100000
106	330	Prednisolone Tablets IP 10 mg	Each uncoated tablet contains: Prednisolone IP 10 mg	10's	10's X 10	2700000
107	337	Clomiphene Citrate Tablets IP 50 mg	Each Film coated tablet contains: Clomiphene Citrate IP 50mg	10's	10's X 10	130000
108	338	Atropine Sulphate Injection IP 0.6mg per ml	Composition: Each ml contains: Atropine Sulphate IP 0.6mg	1ml	1 ml x 10	670000
109	341	Carboxymethylcellulose Sodium Eye Drops IP 0.5% w/v	Composition: Sodium Carboxy Methyl Cellulose IP 0.5% w/v	10 ml Drops	1's X 10	2650000
110	344	Ciprofloxacin Eye Drops IP 0.3% w/v	Composition: Ciprofloxacin Hydrochloride IP eq. To Ciprofloxacin 0.3 % w/v Benzalkonium Chloride Solution IP 0.025% W/V	5 ml Drops	5 ml X 10	2200000
111	345	Gentamicin Eye Drops IP 0.3% w/v	Composition: Gentamicin Sulphate IP equivalent to Gentamicin 0.3 % w/v Benzalkonium Chloride Solution IP 0.02% W/V (As preservative)	10ml Drops	1's X 10	390000
112	351	Xylometazoline Nasal	Composition:	10 ml	1's x 10	1750000

		Drops IP 0.1%w/v	Xylometazoline Hydrochloride IP 0.1% w/v Benzalkonium Chloride Sodium IP 0.012%w/v (As preservative)			
113	356	Lignocaine Injection IP 2% w/v	Each ml contains: Lignocaine Hydrochloride IP 20mg Sodium Chloride IP 6mg Methyl Paraben 1 mg	30 ml Vial	30 ml Vial X 10	100000
114	358	Propofol Injection IP 10 mg per ml	Each ml contains: Propofol 10 mg	10ml Vial	1's X 10	120000
115	359	Tetanus Vaccine IP	Each 0.5 ml contains: Tetanus Toxoid ≥ 5 LF	0.5 ml Ampoules	0.5ml Ampoule X 10	360000
116	360	Mifepristone Tablets IP 200 mg	Each Film coated tablet contains: Mifepristone IP 200mg	1's	1's X 10	100000
117	362	Biphasic Isophane Insulin Injection IP (50:50) 40 IU per ml	Each ml contains: Human Insulin IP 40 IU (50% as Soluble Insulin Injection and 50% as Isophane Insulin Injection) (Human Insulin of recombinant DNA origin)	10ml Vial	1's x 10	1700000
118	367	Voglibose Tablets IP 0.3 mg	Each Film coated tablet contains: Voglibose IP 0.3mg	10's	10's X 10	8000000
119	369	Acarbose Tablets IP 50 mg	Each uncoated tablet contains: Acarbose IP 50mg	10's	10's X 10	1150000
120	371	Voglibose Tablets IP 0.2 mg	Each Film coated tablet contains: Voglibose IP 0.2mg	10's	10's X 10	6400000
121	372	Metformin Hydrochloride Prolonged Release Tablets IP 500 mg	Each film coated Prolonged Release tablet contains: Metformin Hydrochloride IP 500mg	10's	10's X 10	17000000
122	373	Artesunate Injection IP 60 mg	Each vial contains: Artesunate 60 mg The pack also contains: 1 ml ampoule of Sodium Bicarbonate 5% w/v 5 ml ampoule of Sodium Chloride 0.9% w/v	Vial with Diluent	1's X 10	100000
123	376	Imipenem 500mg and Cilastatin 500mg Injection IP	Each Vial contains: Imipenem IP (sterile) equivalent to Anhydrous Imipenem 500mg Cilastatin Sodium IP(Sterile) equivalent to Cilastatin 500mg	Vial with WFI	1's X 10	100000
124	380	Clarithromycin Tablets IP 500 mg	Each Film coated tablet contains: Clarithromycin IP 500mg	4's	(4's X 10)	120000
125	381	Cefixime 200mg and Ofloxacin 200mg Tablets	Each Film coated tablet contains: Cefixime IP (As Trihydrate) equivalent to Anhydrous Cefexime 200mg Ofloxacin IP 200mg	10's	10's X 10	1700000
126	382	Linezolid Tablets IP 600 mg	Each Film coated tablet contains: Linezolid IP 600mg	10's	10's X 10	375000
127	386	Diethylcarbamazine Tablets IP 50 mg	Each uncoated tablet contains: Diethylcarbamazine Citrate IP 50mg	30's	30's x 10	120000

			Excipients q.s.			
128	387	Terbinafine Tablets IP 250mg	Each Film coated tablet contains: Terbinafine Hydrochloride IP equivalent to Terbinafine 250mg	7's	10's X 10	1800000
129	391	Moxifloxacin Tablets 400 mg	Each Film coated tablet contains: Moxifloxacin Hydrochloride IP equivalent to Moxifloxacin 400mg	5's	5's X 10	400000
130	392	Griseofulvin Tablets IP 250 mg	Each uncoated tablet contains: Griseofulvin IP 250 MG	10's	10's X 10	560000
131	412	Azathioprine Tablets IP 50 mg	Each uncoated tablet contains: Azathioprine IP 50mg	10's	10's X 10	170000
132	414	Tranexamic Acid 500mg and Mefenamic Acid 250mg Tablets	Each Film coated tablet contains: Tranexamic Acid IP 500mg Mefenamic Acid IP 250mg	10's	10's X 10	1900000
133	419	Heparin Sodium 50IU and Benzyl Nicotinate 2mg Ointment	Each gram contains: Heparin Sodium 50 IU Benzyl Nicotinate 2mg	20gm Tube	1's x 20	110000
134	422	Torsemide Tablets IP 10mg	Each uncoated tablet contains: Torsemide IP 10mg	15's	15's X 10	3400000
135	432	Olmesartan Medoxomil Tablets IP 40 mg	Each film-coated tablet contains: Olmesartan Medoxomil IP 40 mg	10's	10's X 10	5000000
136	435	Rosuvastatin 10mg and Fenofibrate 160mg Tablets IP	Each Film coated tablet contains: Rosuvastatin Calcium IP equivalent to Rosuvastatin 10mg Fenofibrate IP 160mg	10's	10's X 10	2300000
137	445	Olmesartan 20mg and Amlodipine 5mg Tablets	Each film-coated tablet contains: Olmesartan Medoxomil IP 20mg Amlodipine Besilate IP equivalent to Amlodipine 5mg	10's	10's X 10	1550000
138	450	Labetalol Tablets IP 100 mg	Each Film coated tablet contains: Labetalol Hydrochloride IP 100mg	10's	10's X 10	200000
139	451	Streptokinase Injection IP 15,00,000 IU	Each vial contains: Streptokinase IP 15,00,000 IU	Vial with WFI	1's X 10	110000
140	455	Verapamil Tablets IP 80 mg	Each film-coated tablet contains: Verapamil Hydrochloride IP 80 mg	10's	10's X 10	110000
141	458	Labetalol Injection IP 5 mg per ml	Each ml contains: Labetalol 5 mg	4ml Ampoules	4 ml X 10	130000
142	462	Betamethasone Valerate 0.12%w/w and Clioquinol 3%w/w Cream	Contains: Betamethasone Valerate 0.12% w/w Clioquinol Cream BP 3%w/w	30gm Tube	1's X 20	110000
143	470	Diastase and Pepsin Liquid	Each 5ml contains: Diastase IP (1:1200) 50mg Pepsin IP (1:3000) 10mg	200 ML	1's X 6	400000
144	478	Sodium Picosulphate Tablets 10 mg	Each uncoated tablet contains: Sodium Picosulphate 10mg	10's	10's X 10	300000
145	486	Pancreatin 170mg and Activated Dimethicone 80mg Tablets	Each enteric-coated tablet contains: Pancreatin IP 170mg Activated Dimethicone Tablets IP 80mg	10's	10's X 10	110000
146	489	Sulfasalazine Delayed Release Tablets 1000mg	Each enteric-coated tablet contains: Sulfasalazine 1000mg	10's	10's X 10	350000

147	494	Ispaghula Husk IP	Each 100 gm contains: Ispaghula Husk IP 100 g	100gm Tetra-Pack	100gm Tetrapack X 20	430000
148	496	Dydrogesterone Tablets IP 10 mg	Each film-coated tablet contains: Dydrogesterone IP 10 MG	10's	10's X 10	110000
149	497	Kit of Mifepristone 200 mg (1 Tablet) and Misoprostol 200 mcg (4 Tablets)	Each Combi kit contains: (A) 1 Mifepristone Tablet IP Each uncoated tablet contains: Mifepristone IP 200mg (B) 4 Misoprostol Tablets IP each uncoated tablet contains: Misoprostol IP 200mcg	1's	1's x 10	100000
150	498	Ferrous Ascorbate 100mg and Folic Acid 1.5mg Tablets	Each Film coated tablet contains: Ferrous Ascorbate equivalent to elemental Iron 100mg Folic Acid IP 1.5mg	10's	10's X 10	4600000
151	501	Betamethasone Sodium Phosphate Tablets IP 0.5 mg	Each film-coated tablet contains: BETAMETHASONE SODIUM PHOSPHATE TABLETS IP equivalent to Betamethasone 0.5 MG	20's	20's x 10	810000
152	502	Deflazacort Tablets 6 mg	Each uncoated tablet contains: Deflazacort 6mg	6's	6's X 10	4000000
153	505	Carbimazole Tablets IP 10 mg	Each uncoated tablet contains: CARBIMAZOLE 10 MG	100's	**1's X 10**	150000
154	508	Levetiracetam Tablets IP 500 mg	Each Film coated tablet contains: Levetiracetam IP 500mg	10's	10's X 10	8300000
155	510	Paracetamol 325mg and Tramadol 37.5mg Tablets	Each Film coated tablet contains: Paracetamol IP 325mg Tramadol Hydrochloride IP 37.5mg	10's	10's X 10	2550000
156	511	Paracetamol Tablets IP 650 mg	Each uncoated tablet contains: Paracetamol IP 650mg	15's	15's X 10	7000000
157	515	Mefenamic Acid Suspension 100mg per 5ml	Each 5ml contains: Mefenamic Acid IP 100mg	60 ml	60ml X 10	100000
158	516	Aceclofenac Sustained Release Tablets 200mg	Each film coated sustained release tablet contains: Aceclofenac IP 200mg	10's	10's X 10	1000000
159	517	Thiocolchicoside 4mg and Aceclofenac 100mg Tablets	Each film coated tablet contains: Thiocolchicoside IP 4mg Aceclofenac IP 100mg	10's	10's X 10	800000
160	518	Baclofen Tablets IP 10 mg	Each uncoated tablet contains: Baclofen IP 10mg	10's	10's X 10	1100000
161	519	Ketorolac Tromethamine Tablets IP 10mg	Each Film coated tablet contains: Ketorolac Tromethamine IP 10mg	10's	10's X 10	300000
162	523	Naproxen Tablets IP 500 mg	Each uncoated tablet contains: Naproxen IP 500 mg	15's	15's X 10	220000
163	534	Salbutamol 400mcg and Beclomethasone 200mcg Respicaps	Each hard gelatin capsule for dry powder inhalation contains: Beclomethasone Dipropionate 200mcg Salbutamol sulphate equivalent to Salbutamol 400mcg	30's	30's x 10	110000
164	538	Theophylline Tablets	Each Uncoated Sublingual tablet	10's	10's X 10	130000

		400 mg	contains: Theophylline Anhydrous IP 400mg (In beta cyclodextrin) In a controlled release system			
165	540	Levosalbutamol 1.25mg and Budesonide 1mg Respules	Each 2ml Respule contains: Levosalbutamol Tartrate equivalent to Levosalbutamol 1.25 mg Budesonide 1 mg	2ml Respules	2ml X 10	110000
166	543	Menthol (55 mg ± 5.) Cinnamon (12.5 mg ± 2) and Pine Oil (112.5 mg ± 1) Soft Capsules	Menthol (55 mg ± 5.) Cinnamon (12.5 mg ± 2) and Pine Oil (112.5 mg ± 1) Soft Capsules	10's	10's X 10	110000
167	558	Fluticasone 50mcg and Azelastine 140mcg Nasal Spray	Each Spray delivers: Fluticasone Furoate 27.5 mcg Azelastine Hydrochloride 140 mcg	120MD	1's X 10	110000
168	559	Salbutamol 2mg and Theophylline 100mg Tablets	Each uncoated tablet contains: Salbutamol Sulphate IP equivalent to Salbutamol 2mg Theophylline (anhydrous.) IP 100mg	30's	30's x 10	110000
169	560	Fluticasone Propionate Nasal Spray IP 50 mcg	Each spray delivers: Fluticasone Propionate IP 50 mcg	120MD	1's X 10	110000
170	562	Loratidine Tablets IP 10mg	Each uncoated tablet contains: Loratadine IP 10mg	10's	10's X 10	470000
171	564	Tiotropium Bromide 18mcg and Formoterol Fumarate Dihydrate 12mcg Rotacaps	Each capsule contains: Tiotropium bromide monohydrate Ip equivalent to Tiotropium 18mcg Formoterol Fumarate Dihydrate IP 12mcg	15's	15's X 10	110000
172	565	Tiotropium Bromide 18mcg, Formoterol Fumarate Dihydrate 12mcg and Ciclesonide 400mcg Rotacaps	Each capsule contains: Tiotropium bromide monohydrate Ip equivalent to Tiotropium 18mcg Formoterol Fumarate Dihydrate IP 12mcg Ciclesonide IP 400mcg	15's	15's X 10	110000
173	566	Ipratropium Bromide Respirator Solution 250mcg	Each ml contains: Ipratropium bromide IP 250mcg	15ml	1's X 10	110000
174	574	Rabies Vaccine, Human IP	Anti-Rabies Vaccine (Purified Chick embryo cell) 2.5 IU, 1ml vial	1ml Ampoules	1 ml x 10	110000
175	580	Ginseng, Multivitamins and multi minerals Capsules	Each soft Gelatin Capsule contains: Vitamin A (As Palmitate) IP 1600 IU Vitamin B1 IP 1mg Vitamin B2 IP 1mg Vitamin B3 IP 15mg Vitamin B5 IP 1mg Vitamin B6 IP 0.5mg Vitamin B12 IP 0.5mcg Vitamin C IP 25mg Vitamin D3 IP 100IU Vitamin E Acetate IP 5 IU Folic Acid IP 50mcg Ginseng BP 42.3mg Diabasic Calcium Phosphate IP	10's	10's X 10	12000000

			equivalent to Calcium 75mg Phosphorous 58mg Ferrous Fumarate IP 30mg Zinc Sulphate Monohydrate IP 10mg equivalent to Elemental Zinc 3.64mg Light magnesium Oxide IP 3mg Potassium Chloride IP 2mg Manganese Sulphate USP 0.5mg Anhydrous Copper Sulphate BP 0.5mg Potassium Iodine IP Equivalent to Elemental Iodine 0.1mg			
176	581	Calcium Carbonate 500mg, Calcitriol 0.25mcg and Zinc 7.5mg Capsules	Each soft gel capsule contains: Calcium Carbonate IP 500mg equivalent to elemental Calcium 200mg Calcitriol IP 0.25mcg Zinc Sulphate IP 7.5mg	10's	10's X 10	3200000
177	585	Cholecalciferol Granules 60000 IU per gm	Each sachet contains: Cholecalciferol IP 60000 IU	1 Sachet	1gm x 10	8600000
178	588	Vitamin E Soft gel Capsules 400 mg	Each soft gel capsule contains: Tocopherol Acetate IP 400mg	10's	10's X 10	5600000
179	591	Methylcobalamin Injection 500 mcg	Each ml contains: Methylcobalamin IP 500mcg	1ml Ampoules	1's X 10	720000
180	593	Folic Acid 15mg, Cyanocobalamine 500mcg and Nicotinamide 200mg Injection	Each ml contains: Folic Acid 15 mg Cyanocobalamine 500 mcg Nicotinamide 200 mg Benzyl Alcohol 2.5% v/v Phenol 0.5% w/v (As preservative)	10ml Vial	1's X 10	110000
181	595	Thiamine 100mg, Pyridoxine Hydrochloride 50mg and Cyanocobalamin 1000mcg Injection	Each 2 ml ampoule contains: Mecobalamin IP 1000 mcg Pyridoxine HCl IP 50 mg Thiamine 100 mg	2ml	2ml X 10	110000
182	597	Pyridoxine Tablets IP 50 mg	Each uncoated tablet contains: Pyridoxine Hydrochloride 50mg	10's	10's X 10	100000
183	598	Pregabalin 75mg and Methylcobalamin 750mcg Tablets	Each Film coated tablet contains: Pregabalin IP 75mg Methylcobalamin IP 750mcg	10's	10's X 10	4500000
184	601	Disulfiram Tablets IP 500 mg	Each uncoated tablet contains: Disulfiram 500 mg	4's	(4's X 10)	200000
185	611	Cyproheptadine Hydrochloride Syrup IP 2mg	Each 5ml contains: Cyproheptadine Hydrochloride IP 2mg	200ml	1's x 10	200000
186	613	Diclofenac Potassium 50mg, Paracetamol 325mg and Serratiopeptidase 10mg Tablets	Each film-coated tablet contains: Diclofenac Potassium 50 mg Paracetamol 325 mg Serratiopeptidase 10mg (20,000 serratiopeptidase unit as enteric coated granules)	10's	10's X 10	1400000
187	626	Ketoconazole Shampoo 2% W/V	Ketoconazole Shampoo 2% W/V	100ml Bottle	100ml X 10	650000

188	630	Liquid Paraffin 3.75ml and Milk of Magnesia 11.25ml per 15ml Suspension	Each 15 ml contains: Liquid Paraffin IP 3.75ml Milk of Magnesia IP 11.25ml	170 ml Bottle	1's X 10	180000
189	633	Adapalene 0.1%w/w and Clindamycin Phosphate 1%w/w Gel	Composition: Adapalene 0.1%w/w Clindamycin Phosphate IP 1%w/w	15 gm tubes	1's x 10	250000
190	637	Aceclofenac 100mg, Paracetamol 325mg and Chlorzoxazone 250mg Tablets	Each Film coated tablet contains: Aceclofenac IP 100mg Paracetamol IP 325mg Chlorzoxazone 250mg	10's	10's X 10	2500000
191	645	Nimesulid 100mg, Paracetamol 325mg and Chlorzoxazone 375mg Tablets	Each uncoated tablet contains: Nimesulide 100mg Paracetamol 325mg Chlorzoxazone 375mg	10's	10's X 10	350000
192	648	Diclofenac Dithylamine 1.16%w/w, Linseed Oil 3%w/w, Methyl Salicylate 10%w/w and Menthol 5%w/w Spray	Composition: Diclofenac Diethylamine IP 1.16% Eq. to Diclofenac Sodium 1% w/w Linseed oil BP (Oleum Lini) 3%ww Methyle Salicylate IP 10%W/W Menthol IP 5% W/W Excipients & propellant q.s. to 100% w/w	35gm	1's x 10	3400000
193	649	Dicyclomine Hydrochloride 10mg and Simethicone 40mg Oral Drops	Each ml contains: Dicyclomine Hydrochloride 10mg Simethicone 40mg	10ml Drops	10ml X 10	100000
194	665	Vitamin B Complex and Ascorbic Acid Capsules	Each soft gelatin capsule contains: Thiamine (vit. B1) 10mg Riboflavin (vit. B2) 10mg Niacinamide (vit. B3) 50mg Pyridoxine Hydrochloride (vit. B6) 3mg Cynocobalamine (vit. B12) 5mcg Calcium Pantothenate 12.5mg Folic acid 1mg Ascorbic acid (vitamin C) 150mg	10's	10's X 10	4500000
195	666	Pheniramine Maleate Injection IP 22.75 mg	Each ml contains: Pheniramine Maleate IP 22.75 mg	2ml Ampoules	2ml X 10	200000
196	670	Glucosamine 750mg, Diacerein 50mg and Methylsulfonylmethane 250mg Tablets	Each film-coated tablet contains: Glucosamine Sulphate Potassium Chloride 750 mg Diacerein 50 mg Methylsulfonylmethane 250mg	10's	10's X 10	900000
197	672	Mometasone Furoate Cream IP 0.1%w/w	Composition: Mometasone Furoate IP 0.1%w/w	15gm	1's x 10	480000
198	673	Biotin Tablets 10mg	Each Film coated tablet contains: Biotin 10mg	10's	10's X 10	270000
199	679	Nalidixic Acid Tablets IP 500 mg	Each tablet contains: Nalidixic Acid Tablets IP 500 mg	10's	10's X 10	110000
200	681	Phenazopyridine Hydrochloride Tablet 100mg	Each sugar-coated tablet contains: Phenazopyridine Hydrochloride 100mg	10's	10's X 10	110000
201	685	Pantoprazole Sodium	Each hard gelatin capsule contains:	10's	10's X 10	300000

		40mg (Enteric Coated) and Itopiride Hydrochloride 15mg (Sustained Release) Capsules	Pantoprazole Sodium IP equivalent to Pantoprazole 40mg (as enteric coated pellets) Itopride Hydrochloride 15mg (as sustained release pellets)			
202	697	Sulphacetamide Eye Drop IP 10 % w/v	Contains: Sulphacetamide Sodium 10 % w/v Phenylethyl Alcohol 0.5% v/v (as preservative)	10ml Drops	1's X 10	110000
203	701	Pilocarpine Eye Drops IP 2% W/V	Contains: Pilocarpine Nitrate IP 2% w/v Hydroxypropylmethylcellulose IP 0.35% w/v Chlorbutol IP 0.5% w/v (As preservative)	10ml Drops	1's X 10	110000
204	713	Glibenclamide 5mg and Metformin Hydrochloride 500mg Tablets IP	Each uncoated tablet contains Glibenclamide IP 5mg Metformin Hydrochloride I.P 500mg	10's	10's X 10	6400000
205	717	Etodolac Tablets IP 300mg	Each film-coated tablet contains: Etodolac IP 300mg	10's	10's X 10	150000
206	728	Dextrose 5%w/v and Sodium Chloride 0.9%w/v Injection IP	Dextrose and Sodium Chloride Injection (5% w/v + 0.9% w/v)	500ml FFS bottle	500 ml x 1	1100000
207	739	Cefuroxime Tablets IP 125mg	Each film coated tablet contains: Cefuroxime Axetil IP equivalent to Cefuroxime 125mg	6's	(6's X 10)	100000
208	748	Glimepiride Tablets IP 4mg	Each uncoated tablet contains Glibenclamide IP 4mg	10's	10's X 10	2400000
209	753	Clotrimazole 1%w/v and Beclometasone Dipropionate 0.025%w/v Lotion	Contains: Clotrimazole 1% w/v Beclometasone Dipropionate 0.025% w/v	15ml	12 x 1 x 15 ml	375000
210	759	Rosuvastatin Tablets IP 10mg	Each film coated tablet contains Rosuvastatin Calcium IP equivalent to Rosuvastatin 10mg	15's	15's X 10	6200000
211	764	Etizolam Tablets 0.5mg	Each film coated tablet contains Etizolam 0.5mg	10's	10's X 10	700000
212	769	Acetylsalicylic Acid (Aspirin) Tablets IP 325mg	Each gastro-resistant tablet contains: Aspirin 325mg	14's	14's x 10	1000000
213	784	Amisulpride Tablets IP 50mg	Each uncoated tablet contains Amisulpride IP 50mg	10's	10's X 10	500000
214	796	Aspirin 75mg (Enteric coated) and Atorvastatin 10mg Capsules	Each hard gelatin capsule contains: Atorvastatin Calcium IP equivalent to Atorvastatin 10mg Aspirin IP 75mg (as gastro-resistant tablet IP 75mg)	10's	10's X 10	9000000
215	800	Bacitracin 250 IU, Neomycin 5mg, Sulphacetamide 60mg Dusting Powder	Each gram contains: Neomycin Sulphate 5 mg Bacitracin 250 units Sulphacetamide 60mg	10gm Bottle	10gm Bottle X 20	500000
216	804	Betamethasone	Each ml contains:	1ml	1ml	500000

		Injection IP 4 mg per ml	Betamethasone Sodium Phosphate 4 mg	Ampoules	Ampoule x 10	
217	807	Biphasic Isophane Insulin Injection IP 100 IU/ml (30:70) (30% Soluble Insulin and 70% Isophane Insu	Each ml contains: Human Insulin IP 100 IU (30% Soluble Insulin Injection and 70% Isophane Insulin Injection) Preservative: m-cresol, phenol	3ml Catridge	3 ml X 10	2400000
218	818	Calcium Gluconate Injection IP 10 %	Contains: Calcium Gluconate IP 10 % w/v	10ml Ampoules	1's X 10	300000
219	821	Carvedilol Tablets IP 6.25mg	Each film coated tablet contains Carvedilol IP 6.25mg	10's	10's X 10	3450000
220	830	Chlordiazepoxide 10mg and Trifluoperazine 1mg Tablets	Each uncoated tablet contains Chlordiazepoxide 10mg Trifluoperazine HCL IP equivalent to Trifluoperazine 1mg	10's	10's X 10	120000
221	835	Glucosamine Sulphate 500mg and Chondroitin 400mg Tablets	Each film-coated tablet contains: Chondroitin Sulphate 400mg Glucosamine Sulphate 500mg	10's	10's X 10	300000
222	837	Cilnidipine Tablets IP 20mg	Each film coated tablet contains Cilnidipine IP 20mg	10's	10's X 10	2300000
223	840	Citicoline Tablets IP 500mg	Each film coated tablet contains Citicoline Sodium IP equivalent to Citicoline 500mg	10's	10's X 10	700000
224	865	Diacerein Capsules IP 50mg	Each capsule contains Diacerein IP 50mg	10's	10's X 10	250000
225	879	Drotaverine Hydrochloride Tablets IP 40mg	Each film coated tablet contains Drotaverine Hydrochloride IP 40mg	10's	10's X 10	325000
226	885	Ethinylestradiol 0.05mg and Levonorgestrel 0.25mg Tablets IP	Each uncoated tablet contains: Ethinylestradiol IP 0.05mg Levonorgestrel IP 0.25mg	21's	21's x 10	100000
227	888	Febuxostat Tablets 40mg	Each film coated tablet contains Febuxostat 40mg	10's	10's X 10	3350000
228	889	Febuxostat Tablets 80mg	Each film coated tablet contains Febuxostat 80mg	10's	10's X 10	1350000
229	920	Insulin Regular (R-DNA Origin) Injection 100 IU	Insulin Regular (R-DNA Origin) Injection 100 IU	3ml Cartridge	3 ml X 10	250000
230	926	Ketoconazole Cream 2% w/w	Each gm contains Ketoconazole 20mg	15gm tube	1's x 20	1300000
231	931	Lamotrigine Tablets 100mg	Each uncoated tablet contains: Lamotrigine 100 mg	10's	10's X 10	450000
232	932	Latanoprost Eye Drops IP 0.005% w/v (50mcg per ml)	Each ml contains: Latanoprost IP 50 mcg	2.5ml Drops	2.5 ml x 10	300000
233	934	Lenalidomide Capsules 10mg	Each capsule contains: Lenalidomide 10mg	10's	10's X 10	300000
234	938	Levocarnitine Injections 1gm	Each 5 ml ampoule contain: Levocarnitine Injection 1 g Hydrochloric acid q.s.	5ml Ampoule	5ml X 10	300000

235	944	Levosalbutamol Inhaler 50mcg	Each activation delivers: Levosalbutamol tartrate equivalent to Levosalbutamol 50mcg	200 MDI	1's X 10	300000
236	945	Levosulpiride Tablets 25mg	Each uncoated tablet contains Levosulpiride 25mg	10's	10's X 10	300000
237	949	Lorazepam Tablets IP 2mg	Each uncoated tablet contains Lorazepam IP 2mg	10's	10's X 10	930000
238	951	Lycopene 1000 mcg, Vitamin A 2500 IU, Vitamin E 10 IU, Selenium 35 mcg and Vitamin C 50mg per 5ml Syrup	Each 5 ml contains: Levocarnitine 5% 1000 mcg Vitamin A 2500 IU Vitamin E 10 IU Vitamin C 50 mg Zinc (as Zinc Gluconate) 3 mg Manganese 2 mg Iodine 100 mcg Copper 500 mcg Thiamine HCl 2 mg Riboflavin Sodium Phosphate 3 mg Pyridoxine HCl 1.5 mg	200 ml	1's X 6	900000
239	954	Medroxyprogesterone Acetate Tablets IP 10mg	Each uncoated tablet contains Medroxyprogesterone Acetate IP 10mg	10's	10's X 10	100000
240	957	Memantine Hydrochloride Tablets IP 10mg	Each film-coated tablet contains: Memantine Hydrochloride IP 10mg	10's	10's X 10	200000
241	960	Metformin Sustained Release Tablets IP 850mg	Each film coated Sustained Release tablet contains: Metformin Hydrochloride IP 850mg	10's	10's X 10	3300000
242	965	Miconazole 2%w/w and Fluocinolone Acetonide 0.01%w/w Ointment	Contains: Miconazole Nitrate 2% w/w Fluocinolone Acetonide 0.01% w/w	15gm tube	1's x 20	400000
243	974	Natural Micronized Progesterone Capsules 100mg	Each soft gelatin capsule contains Progesterone 100mg (Natural, Micronized)	10's	10's X 10	100000
244	990	Olanzapine Tablets IP 10mg	Each film coated tablet contains Olanzapine IP 10mg	10's	10's X 10	930000
245	991	Olanzapine Tablets IP 5mg	Each film coated tablet contains Olanzapine IP 5mg	10's	10's X 10	1100000
246	993	Ondansetron Oral Solution IP 2 mg per 5ml	Each 5ml contains Ondansetron Hydrochloride IP equivalent to Ondansetron 2 mg	30ml	1's x 10	325000
247	994	Oxaliplatin Injections IP 50mg	Each vial contains Oxaliplatin IP 50mg	Vial with WFI	1's x 10	100000
248	996	Oxcarbazepine Tablets IP 300mg	Each film coated tablet contains: Oxcarbazepine I P 300mg	10's	10's X 10	2100000
249	1003	Permethrin Cream 5% w/w	Each gm contains Permethrin 50mg Cream Base q.s	30gm Tube	1's X 20	570000
250	1008	Phytomenadione Injection (Vitamin K1) IP 1mg per 0.5ml	Each ml contains: Phytomenadione 2 mg Polyoxyethylated fatty acid derivative 70 mg, dextrose, hydrous 37.5 mg,	0.5ml Ampoule	0.5ml Ampoule X 10	300000

			benzyl alcohol 9 mg added as preservative. May contain hydrochloric acid for pH adjustment.			
251	1024	Promethazine Injection IP 25 mg per ml	Each ml contains: Promethazine Hydrochloride 25 mg	2ml Ampoules	2ml X 10	200000
252	1050	Sertraline Tablets IP 100mg	Each film coated tablet contains: Sertraline Hydrochloride IP equivalent to Sertraline 100 mg	10's	10's X 10	300000
253	1051	Sertraline Tablets IP 25mg	Each film coated tablet contains: Sertraline Hydrochloride IP equivalent to Sertraline 25 mg	10's	10's X 10	420000
254	1059	Sodium Valproate Enteric Coated Tablets IP 200mg	Each enteric coated tablet contains Sodium Valproate IP 200mg	10's	10's X 10	1750000
255	1069	Sulphacetamide Sodium Eye Drop I.P 20% W/V	Each ml contains: Sulfacetamide Sodium IP 20 % w/v Phenylethyl alcohol IP 0.5 % v/v (as preservative)	10ml Drops	1's X 10	100000
256	1098	Metformin Hydrochloride 500mg (Sustained Release) and Voglibose 0.2mg Tablets	Each uncoated bilayered tablet contains Metformin Hydrochloride 500mg (Sustained Release) IP 500mg Voglibose IP 0.2mg	10's	10's X 10	2950000
257	1104	Zoledronic Acid Injection IP 4mg per ml	Each vial contains Zoledronic Acid IP equivalent to Zoledronic Acid (Anhydrous) 4mg Water for Injection IP q.s	5ml Vial with WFI	5 ml Vial X10	100000
258	1105	Zolpidem Tablets IP 10mg	Each film coated tablet contains Zolpidem Tartrate IP 10mg	10's	10's X 10	800000
259	1111	Gabapentin 400mg and Nortriptyline 10mg Tablets	Each film coated tablet contains Gabapentin IP 400mg Nortriptyline Hydrochloride equivalent to Nortriptyline 10mg	10's	10's X 10	1350000
260	1114	Moxifloxacin Hydrochloride Eye Drops IP 0.5% w/v	Each mil contains Moxifloxacin Hydrochloride IP equivalent to Moxifloxacin IP 5.0 mg	5ml Drops	5 ml x 10	650000
261	1125	Aripiprazole Tablets IP 5mg	Each uncoated tablet contains: Aripiprazole IP 5 mg	10's	10's X 10	500000
262	1129	Teneligliptin 20mg and Metformin Hydrochloride 500mg (Sustained Release) Tablets	Each uncoated bilayered tablet contains Teneligliptin Hydrobromide Hydrate equivalent to Teneligliptin 20mg Metformin Hydrochloride IP 500mg (Sustained Release)	10's	10's X 10	5600000
263	1130	Teneligliptin 20mg and Metformin Hydrochloride 1000mg (Sustained Release) Tablets	Each uncoated bilayered tablet contains Teneligliptin Hydrobromide Hydrate equivalent to Teneligliptin 20mg Metformin Hydrochloride IP 1000mg (Sustained Release)	10's	10's X 10	1900000
264	1152	Carbamazepine Prolonged-release	Each film coated prolonged release tablet contains:	10's	10's X 10	1500000

		Tablets IP 200mg	Carbamazepine IP 200 mg			
265	1164	Nandrolone Decanoate Injection IP 50 mg per ml	Each ml contains: Nandrolone decanoate 50mg	2ml Ampoules	2ml x 10	200000
266	1168	Ketorolac Injection IP 30mg per ml	Each vial contains: Ketorolac tromethamine 30 mg	1ml Ampoules	1 ml x 10	200000
267	1170	Acetylcysteine Injection 200 mg per ml	Each ml contains: Acetylcysteine 200 mg	2ml Ampoules	2ml X 10	100000
268	1186	Cyclosporin Capsules IP 25mg	Each soft gelatin capsule contains: Cyclosporine IP 25 mg	5's	(5's X 10)	100000
269	1187	Cyclosporine Capsules IP 100 mg	Each soft gelatin capsule contains: Cyclosporine IP 100 mg	5's	5's X 10	100000
270	1199	Hydroxyurea Capsules IP 500mg	Each Hard gelatin capsule contains Hydroxyurea IP 500mg	10's	10's X 10	200000
271	1203	Protamine Sulphate Injection IP 10mg per ml	Each ml contains: Protamine Sulphate 10 mg	5ml vial/ampoule	5 ml Vial X10	200000
272	1211	Docetaxel Injection IP 80 mg	Each ml contains Docetaxel trihydrate IP equivalent to Docetaxel anhydrous 40mg Water for Injection IP q.s	Vial with WFI	1's x 10	100000
273	1212	Docetaxel Injection IP 120 mg	Each ml contains Docetaxel trihydrate IP equivalent to Docetaxel anhydrous 40mg Water for Injection IP q.s	Vial with WFI	1's x 10	100000
274	1214	Gefitinib Tablets IP 250 mg	Each film coated tablet contains Gefitinib IP 250 mg	10's	10's X 10	100000
275	1215	Pemetrexed Injection IP 100 mg	Each vial contains Pemetrexed Disodium Heptahydrate IP equivalent to Pemetrexed IP 100 mg Water for Injection IP q.s	VIAL	1's X 10	100000
276	1216	Pemetrexed Injection IP 500 mg	Each vial contains Pemetrexed Disodium Heptahydrate IP equivalent to Pemetrexed IP 500 mg Water for Injection IP q.s	VIAL	1's X 10	100000
277	1217	Temozolomide Capsules IP 100mg	Each hard gelatin capsule contains Temozolomide IP 100mg	5's in Bottle	(5's X 10)	100000
278	1218	Temozolomide Capsules IP 250 mg	Each hard gelatin capsule contains Temozolomide IP 250mg	5's	(5's X 10)	100000
279	1219	Amino Acid Solution for IV	Nutritive infusion of Pure Crystalline Amino Acids	200 ml Glass Bottle	1's X 6	200000
280	1226	Triamcinolone Injection 40mg per ml	Each ml contains: Triamcinolone Acetonide IP 40 mg Benzyl Alcohol IP 0.9%w/v (as preservative)	1ml Ampoules	1ml Ampoule x 10	200000
281	1227	Triamcinolone Tablets IP 4mg	Each uncoated tablet contains: Triamcinolone IP 4 mg	10's	10's X 10	200000
282	1231	Vitamin E Acetate 200mg and Levocarnitine 150mg Tablets	Each film coated tablet contains: Tocopherol Acetate IP 200 mg (as 50% powder) L-Carnitine-L-Tartrate equivalent to Levocarnitine USP 150	10's	10's X 10	250000

			mg			
283	1237	Methyldopa Tablets IP 500 mg	Each film coated tablet contains: Methyldopa IP equivalent to anhydrous Methyldopa 500 mg	10's	10's X 10	100000
284	1241	Cefaclor Dispersible Tablets 250 mg	Each dispersible tablet contains: Cefaclor IP equivalent to anhydrous Cefaclor 250 mg	10's	10's X 10	200000
285	1255	Acebrophylline 200mg (Sustained Release) and Montelukast 10mg Tablets	Each film coated bilayered tablet contains: Montelukast Sodium IP equivalent to Montelukast 10 mg (in immediate release form) Acebrophylline 200 mg (in sustained release form)	10's	10's X 10	480000
286	1257	Allylestrenol Tablets 5 mg	Each Film coated tablet contains: Allylestrenol 5 mg	10's	10's X 10	100000
287	1281	Chlordiazepoxide Tablets IP 10 mg	Each sugar coated tablet contains Chlordiazepoxide IP 10 mg	10's	10's X 10	200000
288	1307	Ethinylestradiol 0.03mg and Desogestrel 0.15mg Tablets	Each uncoated tablet contains Ethinylestradiol 0.03mg Desogestrel 0.15mg Tablets	21's	21's x 10	100000
289	1308	Ethinylestradiol 0.03mg and Levonorgestrel 0.15mg Tablets IP	Each uncoated tablet contains: Levonorgestrel IP 0.15 mg Ethinyloestradiol IP 0.03 mg	21's	21's x 10	100000
290	1312	Flavoxate Tablets IP 200 mg	Each film coated tablet contains Flavoxate Hydrochloride IP 200 mg	15's	15's X 10	200000
291	1315	Fluticasone Furoate Nasal Spray 27.5mcg	Each spray delivers: Fluticasone Furoate 27.5 mcg	120 MDI	1's X 10	200000
292	1319	Gabapentin Tablets IP 100 mg	Each film coated tablet contains Gabapentin IP 100 mg	10's	10's X 10	1000000
293	1328	Isoxsuprine Injection IP 5 mg	Each ml contains: Isoxsuprine Hydrochloride IP 5 mg WFI IP q.s	2ml Vial	2ml X 10	100000
294	1341	Mebendazole Tablets IP 100 mg	Each uncoated tablet contains: Mebendazole 100 mg	6's	(6's X 10)	100000
295	1342	Mebeverine Hydrochloride Tablets IP 200mg	Each sugar-coated tablet contains: Mebeverine Hydrochloride IP 200 mg	10's	10's X 10	100000
296	1354	Modafinil Tablets IP 200mg	Each uncoated tablet contains Modafinil IP 200mg	10's	10's X 10	100000
297	1359	Naproxen Tablets IP 250 mg	Each uncoated tablet contains: Naproxen 250 mg	15's	15's X 10	200000
298	1375	Phenobarbitone Tablets IP 60 mg	Each uncoated tablet contains: Phenobarbitone 60 mg	30's	30's x 10	600000
299	1414	Terlipressin Injection 1000 mcg (1 mg)/10ml	Each 10ml contains: Terlipressin 1 mg	10ml Vial	1's X 10	100000
300	1418	Tigecycline Injection 50 mg	Each vial contains: Tigecycline 50 mg lyophilized powder Water for Injection IP q.s	5ml Vial with WFI	5 ml Vial X10	100000
301	1431	Valethamate Injection	Each ml contains:	1ml	1ml	100000

		8 mg per ml (For IM/IV use)	Valethamate Bromide 8 mg Sodium Chloride IP 8 mg WFI q.s.	Ampoules	Ampoule x 10	
302	1437	Cefpodoxime Proxetil Oral Suspension IP 50mg	Each 5 ml of the Reconstituted suspension contains: Cefpodoxime Proxetil IP equivalent to equivalent to Cefpodoxime 50mg	30 ml Bottle with Diluent	1's x 10	170000
303	1450	Pyrantel Pamoate Oral Suspension IP 250mg/5ml	Each 5ml contains: Pyrantel Pamoate IP 250 mg	10ml Bottle	10ml X 10	200000
304	1451	Theophylline Controlled release tablets 400 mg	Each uncoated tablet contains: Theophylline Anhydrous IP 400mg (in controlled release form)	10's	10's X 10	100000
305	1452	Pyridoxine Hydrochloride Sustained release tablets 100mg	Each Sustained release tablet contains: Pyridoxine Hydrochloride IP 100 mg	10's	10's X 10	150000
306	1454	Terbutaline Sulphate and Bromhexine Hydrochloride Syrup	Each 5ml contains: Terbutaline Sulphate 1.25MG, Ambroxol 30mg, Guaifenesin 50mg and Menthol 2.5 mg	100ml Bottle	100ml X 10	200000
307	1457	Luliconazole Cream 1% w/w	Contains: Luliconazole 1% w/w Preservatives: Methylparaben 0.14% w/w Benzyl Alcohol 1% w/w in a Cream base q.s.	10gm tube	20 x 1's	1850000
308	1485	Mesalazine Prolonged release Tablets IP 1200 mg	Each gastro-resistant prolonged release tablet contains: Mesalazine 1200 mg (Prolonged Release)	10's	10's X 10	5000000
309	1486	Propranolol Capsules 40 mg	Each Extended-release capsule contains: Propranolol 40 mg	10's	10's X 10	10000000
310	1487	Selenium Sulfide Shampoo 2.5% w/v	Contains: Selenium Sulfide 2.5% w/v	120ml Bottle	1's X 10	450000
311	1494	Aceclofenac 100mg, Paracetamol 325mg and Rabeprazole 10mg Tablets	Each film coated tablet contains: Aceclofenac 100 mg Paracetamol 325mg Rabeprazole Sodium 10mg (as enteric coated form)	10's	10's X 10	2500000
312	1495	Aceclofenac 100mg, Paracetamol 325mg and Tizanidine 10mg Tablets	Each film coated tablet contains: Aceclofenac 100 mg Paracetamol 325mg Tizanidine Hydrochloride equivalent to Tizanidine 2mg	10's	10's X 10	5000000
313	1496	Aciclovir Dispersible Tablets IP 400 mg	Each dispersible uncoated tablet contains: Aciclovir IP 400 mg	5's	5's X 10	1200000
314	1497	Acitretin Capsules IP 25 mg	Each hard gelatin capsule contains: Acitretin IP 25mg	10's	10's X 10	200000
315	1500	Aflibercept Injection 2mg per 0.05ml	Each ml contains: Aflibercept 40 mg	1ml Ampoules	1ml Ampoule x 10	200000
316	1501	Amantadine	Each hard gelatin capsule contains:	10's	10's X 10	1200000

		Hydrochloride Capsules IP 100 mg	Amantadine Hydrochloride IP 100 mg			
317	1503	Amlodipine Besilate 5mg and Bisoprolol Fumarate 5mg Tablets	Each film coated tablet contains: Amlodipine Besilate equivalent to Amlodipine 5mg Bisoprolol Fumarate 5mg	10's	10's X 10	5000000
318	1506	Amoxycillin 80mg and Potassium Clavulanate 11.4mg Oral Suspension IP	Each ml contains: Amoxycillin Trihydrate IP equivalent to Amoxycillin 80mg Potassium clavulanate diluted IP equivalent to Clavulanic Acid 11.4mg	Vial with Diluent	1's X 10	2500000
319	1507	Amoxycillin 250mg, Dicloxacillin 250mg and Lactic Acid Bacillus 2.5 billion Capsules	Each hard gelatin capsule contains: Amoxycillin Trihydrate equivalent to Amoxycillin 250 mg Dicloxacillin Sodium equivalent to Dicloxacillin 250 mg Lactic acid Bacillus 2.5 billion spores	10's	10's X 10	5000000
320	1508	Ampicillin 250mg and Cloxacillin 250mg Capsules	Each Hard gelatin capsule contains: Ampicillin Trihydrate equivalent to Ampicillin 250 mg Cloxacillin Sodium IP equivalent to Cloxacillin 250 mg	10's	10's X 10	2500000
321	1510	Anti-D (Rho) Immunoglobulin (Monoclonal) 300 mcg	Each ml contains: Monoclonal Anti-D I.H 300 mcg	1ml Vial	1ml x 10	200000
322	1527	Betamethasone Valerate 0.12%w/w, Gentamicin 0.1%w/w and Miconazole Nitrate 2%w/w Cream	Betamethasone Valerate 0.12% w/w Gentamicin 0.1% w/w Miconazole Nitrate 2% w/w	20gm Tube	1's X 20	2500000
323	1529	Bimatoprost Ophthalmic Solution 0.01% w/v	Each ml contains: Bimatoprost 0.1 mg	3ml Drops	1's X 10	2500000
324	1532	Botulinum Toxin Type A 100 IU	Each vial contains: Botulinum Toxin Type A 100 IU (from Clostridium botulinum)	Vial	1's X 10	200000
325	1534	Brimonidine Tartrate Eye drops IP 0.1% w/v	Brimonidine Tartrate IP 0.1% w/v	5ml Drops	1's X 10	1200000
326	1539	Calcium Gluconate 50mg and Calcium Lactobionate 87.5mg Injection	Each ml Contains: Calcium Gluconate 50mg Calcium Lactobionate 87.5mg equivalent to elemental calcium 9mg	10ml	1's X 10	200000
327	1540	Calcium (from Coral Grains) 500mg and Vitamin D-3 500IU Tablets	Each film coated tablet contains: Calcium carbonate (from Coral Grains) equivalent to Elemental Calcium 500 mg Vitamin D3 (as stabilized granules) 500 IU	10's	10's X 10	10000000
328	1543	Camylofin Dihydrochloride 25mg and Paracetamol 300mg Tablets	Each film caoted tablet contains: Camylofin Dihydrochloride 25 mg Paracetamol 300 mg	10's	10's X 10	1200000

329	1556	Cephalexin Extended-Release Tablets 750mg	Each Extended-Release film coated tablet contains: Cephalexin equivalent to anhydrous Cephalexin 750 mg	10's	10's X 10	200000
330	1557	Cerebroprotein Hydrolysate Injection 30mg	Each lyophilized vial contains: Cerebroprotein Hydrolysate 1050mg (approx) equivalent to Nitrogen 30 mg	Vial wth WFI	1's X 10	200000
331	1558	Cerebroprotein Hydrolysate Injection 60mg	Each Vial contains: Cerebroprotein Hydrolysate 60mg	Vial wth WFI	1's X 10	200000
332	1562	Chlordiazepoxide 5mg and Amitriptyline Hydrochloride 12.5mg Tablets	Each film coated tablet contains: Amitriptyline Hydrochloride equivalent to Amitriptyline 12.5mg Chlordiazepoxide 5mg	10's	10's X 10	5000000
333	1568	Cinnarizine Tablets IP 75mg	Each uncoated tablet contains: Cinnarizine IP 75mg	10's	10's X 10	5000000
334	1575	Clobetasol Propionate 0.05%w/w and Gentamicin 0.1%w/w Cream	Contains: Clobetasol Propionate 0.05% w/w Gentamicin 0.1% w/w	25gm Tube	1's X 10	5000000
335	1581	Clopidogrel 75mg and Aspirin 150mg Capsules	Each hard gelatin capsule contains: Clopidrogrel Bisulphate equivalent to Clopidrogrel 150mg Aspirin IP 75mg (as gastro-resistant)	10's	10's X 10	10000000
336	1582	Clotrimazole 1%w/v and Selenium Sulfate 2.5%w/v Suspension	Contains: Clotrimazole 1% w/v Selenium Sulfate 2.5% w/v	75 ml	75g X 10	200000
337	1584	Coenzyme Q10 (Ubidecarenone) and L-Carnitine Tablets	Each film coated tablet contains: Ubidocarenone 30 mg L-Carnitine L-Tartrate equivalent to L-carnitine 500 mg	10's	10's X 10	5000000
338	1587	Colistin Sulphate Oral Suspension IP 12.5 mg per 5ml	Each pack contains: A. One bottle of Colistin sulphate oral suapension IP 12.5mg/5ml On reconstituted each 5 ml contains: Colistin Sulphate IP equivalent to Colostin 12.5 mg B. One ampoule of Sterile Water for Injection IP 25 ml Net content: 12.5 g/ 30 ml	30ml Vial with WFI	30ml X 10	200000
339	1588	Collagen Peptide (Type I) 40mg, Sodium Hyaluronate 30mg, Chondroitin Sulfate 200mg and Vitamin C 35mg Tablets	Each film coated tablet contains: Chondroitin Sulfate Sodium 200 mg Collagen Peptide Type I 40 mg Sodium Hyaluronate 30 mg Vitamin C 35 mg	10's	10's X 10	5000000
340	1589	Combi pack of Clarithromycin 500mg Tablets, Pantoprazole 40mg Tablets and Amoxycillin 750mg Tablets	Each strip contains: A. Clarithromycin Tablets IP 500mg (2 tablets) Each film coated tablet contains: Clarithromycin IP 500 mg	6's	6's X 10	200000

			B. Pantoprazole Tablets IP 40mg (2 tablets) Each enteric coated tablet contains: Pantoprazole Sodium IP equivalent to Pantoprazole 40mg C. Amoxycillin Tablets 750mg (2 tablets) Amoxycillin Trihydrate IP equivalent to Amoxycillin 750mg			
341	1590	Dabigatran Etexilate Mesilate Capsules 110 mg	Each hard gelatin capsule contains: Dabigatran Etexilate Mesilate 126.83 mg equivalent to Dabigatran etexilate 110mg	10's	10's X 10	10000000
342	1591	Dabigatran Etexilate Mesilate Capsules 150 mg	Each hard capsule contains: Dabigatran Etexilate Mesilate 172.95 mg equivalent to Dabigatran etexilate 150mg	10's	10's X 10	5000000
343	1594	Diclofenac Diethylamine 1.16% w/w, Thiocholchicoside 0.125% w/w, Linseed Oil 3% w/w, Methylsalicylate 10% w/w and Menthol 5% w/w Gel	Contains: Diclofenac Diethylamine 1.16% w/w equivalent to Diclofenac 1% w/w Thiocholchicoside 0.125% w/w Linseed Oil 3% w/w Methylsalicylate 10% w/w Menthol 5% w/w	30gm Tube	30g Tube X 10	10000000
344	1596	Diclofenac Potassium 50mg and Metaxalone 400mg Tablets	Each uncoated tablets contains: Diclofenac potassium 50mg Metaxalone 400mg	10's	10's X 10	1200000
345	1598	Pancreatin 170 mg (containing 15000 units of Amylase activity, 4000 units of Lipase activity, 15000 units of Protease activity) and Sodium Tauroglycocholate 65mg Digestive Enzyme Tablets	Each enteric coated tablet contains: Pancreatin 170 mg (containing 15,000 units of Amylase activity 4,000 units of Lipase activity 15,000 units of Protease ase activity) Sodium Tauroglycocholate 65 mg	10's	10's X 10	2500000
346	1599	Diltiazem Hydrochloride Extended-Release Capsules 120 mg	Each Hard gelatin capsule contains: Diltiazem Hydrochloride 120 mg (as Extended-Release pellets)	10's	10's X 10	10000000
347	1600	Diosmin Tablets (Micronized)	Each film coated tablet contains: Diosmin (micronized) 450 mg Flavanoids exposed as hesperidine 50 mg	10's	10's X 10	500000
348	1601	Diphenoxylate Hydrochloride 2.5mg and Atropine sulphate	Each Tablet Contains: Diphenoxylate HCL 2.5 mg equivalent to Diphenoxylate 2.3 mg	10's	10's X 10	200000

		0.025mg Tablet	Atropine sulphate 0.025mg equivalent to Atropine 0.01 mg			
349	1605	Dosulepin (or Dothiepin) Tablets 25 mg	Each film coated tablet contains: Dosulepin Hydrochloride 55 mg (Formely Dothiapine Hydrochloride)	10's	10's X 10	10000000
350	1606	Dosulepine (or Dothiepin) Tablets IP 75mg	Each film coated tablet contains: Dosulepin Hydrochloride 75 mg (Formely Dothiapine Hydrochloride)	10's	10's X 10	2500000
351	1608	Efavirenz 600mg, Emtricitabine 200mg and Tenofovir Disoproxil Fumarate 300mg Tablets IP	Each film coated tablet contains: Efavirenz IP 600mg Emtricitabine IP 200mg Tenofovir Disoproxil Fumarate IP 300mg	30's	30's x 10	200000
352	1613	Eplerenone Tablets 25 mg	Each film coated tablet contains: Eplerenone 25 mg	10's	10's X 10	5000000
353	1614	Ergotamine 1mg, Caffeine 100mg, Paracetamol 250mg and Prochlorperazine 2.5mg Tablets	Each uncoated tablet contains: Ergotamine Tartrate 1 mg Caffeine (Monohydrate) 100 mg Paracetamol 250 mg Prochlorperazine Maleate 2.5 mg	10's	10's X 10	5000000
354	1615	Erythromycin Estolate Tablets 500 mg	Each uncoated tablet contains: Erythromycin Estolate 500 mg	10's	10's X 10	200000
355	1616	Etophylline 231mg (Sustained Release), Theophylline 69mg (Sustained Release) and Montelukast 10mg Tablets	Each uncoated bilayer tablet contains: Etofylline 231mg Theophylline anhydrous equivalent to theophylline hydrate 69mg (As sustained release) Montelukast sodium eq. to Montelukast 10mg	10's	10's X 10	2500000
356	1619	Eucalyptol 0.092%w/v, Menthol 0.042%w/v, Methyl salicylate 0.060%w/v and Thymol 0.064%w/v Mouth wash	Contains: Eucalyptol 0.092% w/v Menthol 0.042% w/v Methyl salicylate 0.060% w/v Thymol 0.064% w/v	200ml	1's X 6	1200000
357	1624	Flupentixol 0.5mg and Melitracen 10mg Tablets	Each film coated tablet contains: Flupentixol Hydrochloride equivalent to Flupentixol 0.5 mg Melitracen Hydrochloride equivalent to Melitracen 10 mg	10's	10's X 10	1200000
358	1628	Formoterol Fumarate 12mcg and Budesonide 400mcg Powder for Inhalation IP	Each Capsule Contains: Formoterol Fumarate 12 mcg (as Formoterol Fumarate Dihydrate) Budesonide 400 mcg	30's	30's x 10	2500000
359	1630	Formoterol Fumarate 6mcg and Budesonide 400mcg Powder for Inhalation IP	Each Hard Gelatin Capsule for Dry Powder Inhalation Contains: Formoterol Fumarate 6 mcg (as Formoterol Fumarate Dihydrate) Budesonide 400 mcg	30's	30's x 10	2500000
360	1633	Formoterol Fumarate 6mcg and Fluticasone Propionate 250mcg	Each Capsule Contains: Formoterol Fumarate 6 mcg (as Formoterol Fumarate Dihydrate)	30's	30's x 10	5000000

		Powder for Inhalation	Fluticasone Propionate 250 mcg			
361	1635	Framycetin Skin Cream 1 %	Contains: Framycetin Sulphate 1% w/w	30gm Tube	30g tube X 20	5000000
362	1637	Fungal Diastase 180mg, Papain 60mg and Activated Charcoal 75mg Tablets	Each film coated tablet contains: Fungal Diastase 180 mg Papain 60 mg Activated Charcoal 75 mg	10's	10's X 10	1200000
363	1638	Fusidic Acid 20% w/w and Betamethasone Valerate 0.1% w/w Cream	Each g contains: Fusidic Acid 20 g Betamethasone Valerate 1 g	15gm tube	1's x 20	2500000
364	1643	Glargine 100 IU Pre-filled Disposable Pen	Pre-filled pen of 3ml solution for injection	3ml Pre-filled Pen	3ml Pre-filled Pen X 10	10000000
365	1645	Metformin 500mg (Extended Release) and Gliclazide 60mg Tablets	Each film-coated tablet contains: Gliclazide 60mg Metformin 500 mg (Extended Release)	10's	10's X 10	10000000
366	1647	Metformin 850mg (Prolonged release) and Glimepiride 3mg IP Tablets	Each uncoated tablet contains: Glimepiride 3 mg Metformin 850 mg	10's	10's X 10	10000000
367	1650	Glucosamine 750mg and Chondroitin 100mg Tablets	Each fil coated tablet contains: Glucosamine 750 mg Chondroitin 100 mg	10's	10's X 10	1200000
368	1659	Human Normal Immunoglobulin 5% Solution I.V use only	Human Normal Immunoglobulin for I.V administration. 1 ml solution contains: 5% Human Normal Immunoglobulin	100ml Bottle	100ml X 10	200000
369	1660	Human Normal Immunoglobulin for IM admin 1 ml solution contains: 16.5% HN Immunoglobulin	Human Normal Immunoglobulin for I.M administration. 1 ml solution contains: 16.5% Human Normal Immunoglobulin	2ml vial	2ml X 10	200000
370	1665	Indacaterol 110mcg and Glycopyrronium 50mcg Inhalation Powder, Hard Capsules	Each capsule contains: 143 mcg Indacaterol maleate equivalent to 110 mcg Indacaterol and 63 mcg Glycopyrronium Bromide BP equivalent to 50 mcg Glycopyrronium	30 capsules and 1 inhaler	1 X 10	500000
371	1668	Carbonyl Iron 100mg, Folic Acid 1.5mg and Vitamin B12 15mcg Capsules	Each Capsule contains: Carbonyl Iron 100 mg Folic Acid 1.5 mg Cynocobalamine (Vitamin B12) 15 mcg	10's	10's X 10	10000000
372	1669	Isosorbide 20mg and Hydralazine 37.5mg Tablets	Each film-coated tablet contains: Isosobide 20mg Hydralazine 37.5 mg	10's	10's X 10	10000000
373	1673	L-Methylfolate 2.8mg, Methylcobalamin 2mg & vitamin B6 25mg Tablets	Each Uncoated tablets contains: Each Uncoated Dispersible tablets contains: L- Methyle folate 2.8mg Pyridoxal -5 Phosphate 2 mg Methylcobalamin 25mg	10's	10's X 10	5000000

374	1675	L- Ornithine L-Aspartate Infusion 5gm per 10ml	Each 10ml contains: L- Ornithine L-Aspartate 5g	10ml	1's X 10	200000
375	1676	Lactitol 10 gm and Ispaghula 3.5 gm Granules	Each 15 gm of Granules contains: Lactitol 10 gm Ispaghula 3.5 gm	180gm Jar	1's X 10	2500000
376	1678	L-carnitine 340mg, Ubidecarenone 50mg, Zinc 5mg, Lycopene 2.5mg and Astaxanthin 8mg Tablets	Each film coated tablet contains: L-Carnitine Fumarate equivalent to L-Carnitine 340 mg Ubidocarenone 50 mg Zinc Ascorbate equivalent to Elemental Zinc 5 mg Lycopene (as 6% powder) 2.5 mg Astaxanthin (as 10% powder) 8 mg	10's	10's X 10	5000000
377	1684	Levodopa 100mg and Carbidopa 25mg Tablets IP	Each tablet contains: Carbidopa 25 mg Levodopa 100 mg	10's	10's X 10	10000000
378	1686	Levosalbutamol 100mcg and Beclomethasone 100mcg Rotacaps	Each Capsule Contains: Levosalbutamol Sulphate equivalent to Levosalbutamol 100mcg Beclomethasone Dipropionate 100mcg	30's	30's x 10	2500000
379	1687	Levosalbutamol 100mcg and Beclomethasone 50mcg Rotacaps	Each Capsule Contains: Levosalbutamol Sulphate equivalent to Levosalbutamol 100mcg Beclomethasone Dipropionate 50mcg	200 MDI	1's X 10	2500000
380	1688	Levosalbutamol 200mcg and Beclomethasone 100mcg Rotacaps	Each Capsule Contains: Levosalbutamol Sulphate equivalent to Levosalbutamol 200mcg Beclomethasone Dipropionate 100mcg	30's	30's x 10	2500000
381	1689	Levosalbutamol 1.25mg and Budesonide 0.5mg respules	Each 2.5ml respules contains: Levosalbutamol Hydrochloride equivalent to Levosalbutamol 1.25mg Budesonide 0.5mg	2.5ml	2.5ml X 10	1200000
382	1690	Levosalbutamol 100mcg and Ipratropium 40mcg Rotacap	Each Capsules contains: Levosalbutamol sulphate equivalent to Levosalbutamol 100mcg Ipratropium bromide equivalent to ipratropium 40mcg	30's	30's x 10	2500000
383	1692	Levosalbutamol Respules 0.63mg per 2.5ml	Each 2.5ml Respules contains: Levosalbutamol Sulphate equivalent to Levosalbutamol 0.63mg	2.5ml	2.5ml X 10	200000
384	1697	Linomycin Injection 300mg per 2ml	Each 2ml Contains: Linomycine hydrochloride equivalent to Linomycin 300mg	2ml	2ml X 10	200000
385	1700	Measles Vaccine (Live) 1000ccid50, Mumps Virus Vaccine 5000ccid50 and Rubella Vaccine (live) 1000ccid50 IP	Measles Vaccine (Live) 1000ccid50 Mumps Virus Vaccine 5000ccid50 Rubella Vaccine (live) 1000ccid51	0.5ml vial	1's X 10	200000
386	1703	Metadoxine 500mg,	Each film coated tablets contains:	10's	10's X 10	2500000

		Silymarin 140mg, L-Ornithin L- Aspartate 150mg Tablets	Metadoxine 500mg Silymarin 140mg L- Ornithin L- Aspartate 150mg			
387	1705	Metoprolol 25mg (Extended Release) and Ramipril 2.5mg Tablet	Each film-coated tablet contains: Metoprolol 25 mg (Extended Release) Ramipril 2.5 mg	10's	10's X 10	2500000
388	1706	Metoprolol 50mg (Extended Release) and Ramipril 5mg Tablet	Each film-coated tablet contains: Metoprolol 50 mg (Extended Release) Ramipril 5 mg	10's	10's X 10	2500000
389	1707	Metoprolol Succinate extended-release capsules IP 50mg	Each hard gelatin capsules contains: Metoprolol Succinate Equivalent to Metoprolol tartrate 50mg	10's	10's X 10	10000000
390	1710	Minoxidil 5% and Finasteride 0.1% Topical Solution	Each 60 ml solution contains: Minoxidil 5% w/v Finasteride 0.1% w/v	60 ml	60ml Bottle X 10	500000
391	1714	Naproxen 250 mg and Domperidone 10 mg Tablet	Each film-coated tablet contains: Naproxen 250 mg Domperidone 10 mg	10's	10's X 10	10000000
392	1715	Naproxen 500 mg and Domperidone 10 mg Tablet	Each film-coated tablet contains: Naproxen 500 mg Domperidone 10 mg	10's	10's X 10	10000000
393	1716	Nebivolol 5 mg and S-Amlodipine 2.5 mg Tablet	Each uncoated tablet contains: Nebivolol 5 mg S- Amlodipine 2.5 mg	10's	10's X 10	1200000
394	1717	Neomycin 3400IU, Polymyxin B Sulfates 5000IU and Bacitracin Zinc 400IU Ophthalmic Ointment	Each contains: Neomycin 3400 IU Polymyxin B Sulfates 5000 IU Bacitracin Zinc 400 IU	5gm Tube	5gm Tube X 20	2500000
395	1718	Nicorandil Tablet IP 10mg	Each uncoated tablet contains: Nicorandil 10 mg	10's	10's X 10	10000000
396	1719	Nicorandil Tablet IP 5mg	Each uncoated tablet contains: Nicorandil 5 mg	10's	10's X 10	10000000
397	1720	Nicoumalone/Acenocoumarol Tablets IP 1 mg	Each uncoated tablet contains: Nicoumalone/Acenocoumarol IP 1mg	10's	10's X 10	10000000
398	1721	Nicoumalone/Acenocoumarol Tablets IP 3 mg	Each uncoated tablet contains: Nicoumalone/Acenocoumarol IP 3mg	10's	10's X 10	10000000
399	1735	Orciprenaline Tablet 10 mg	Each uncoated tablet contains: Orciprenaline 10 gm	10's	10's X 10	200000
400	1737	Oxaceprol Capsules 200mg	Each Capsule contains: Oxaceprol Capsules 200mg	10's	10's X 10	200000
401	1738	Pancreatin 100mg and Ornithine 150mg Tablet	Each enteric coated Tablet contains: Pancreatin 100 mg Ornithine 150 mg	10's	10's X 10	200000
402	1739	Pancreatin Capsule 10000 mg	Each capsule contains: Pancreatin 10000 mg	10's	10's X 10	10000000
403	1740	Pancreatin Capsule 25000 mg	Each capsule contains: Pancreatin 25000 mg	10's	10's X 10	5000000
404	1747	Paracetamol 162.5 mg	Each Film-coated tablet contains:	10's	10's X 10	200000

		and Tramadol 18.75 mg Tablet	Paracetamol 162.5 mg Tramadol 18.75 mg			
405	1748	Paracetamol 250 mg, Caffeine 50 mg and Phenazone 150 mg Tablet	Each uncoated tablet contains: Paracetamol 250 mg Caffeine 50 mg Phenazone 150 mg	10's	10's X 10	2500000
406	1751	Paracetamol 500mg and Caffeine 25mg Tablet IP	Each uncoated tablet contains: Paracetamol 500 mg Caffeine 25 mg	10's	10's X 10	5000000
407	1752	Paracetamol 500mg and Chlorzoxazone 250mg Tablet	Each Film-coated tablet contains: Paracetamol 500 mg Chlorzoxazone 250 mg	10's	10's X 10	2500000
408	1753	Paracetamol 500 mg, Phenylephrine 10 mg and Chlorpheniramine 2 mg Tablet	Each Film-coated tablet contains: Paracetamol 500 mg Phenylephrine 10 mg Chlorpheniramine 2 mg	10's	10's X 10	10000000
409	1761	Pirfenidone Tablets IP 200mg	Each Film-coated tablet contains: Piracetam 200 mg	10's	10's X 10	200000
410	1763	Prazosin Extended Release Tablets 5mg	Each film coated GITS tablet contains : Prazosin 5 mg	10's	10's X 10	10000000
411	1767	Probiotic Microbes Capsules 5mg	Each capsule contains: Probiotic Microbes 5 mg	10's	10's X 10	2500000
412	1772	Prulifloxacin Tablet 600 mg	Each Film-coated tablet contains: Prulifloxacin 600 mg	5's	5's X 10	200000
413	1773	Quiniodochlor Tablet IP 250 mg	Each uncoated tablet contains: Quiniodochlor 250 mg	10's	10's X 10	200000
414	1776	Ramosetron Tablet 5 mcg	Each uncoated tablet contains: Ramosetron 5 mcg	10's	10's X 10	200000
415	1779	Reteplase-Recombinant Tissue Plasminogen Activator 18mg	Each kit contains: Reteplase- Recombinant Tissue Plasminogen Activator 18mg	Vial with WFI	1's X 10	200000
416	1782	Rosehip Extract 275mg, Devil's Claw Extract (20%) 100mg and Boswellia serrata Extract (65%) 307.5mg Capsules	Each Capsule contains: Rosehip Extract 275mg DevilsClaw extract (20%) 100mg Boswella serrata Extract (65%) 307.5mg	10's	10's X 10	5000000
417	1789	S(-) Amlodipine 2.5mg and Atenolol 50mg Tablets	Each uncaoted tablet contains: S(-) Amlodipine Besylate S(-) Amlodipine 2.5 mg Atenolol 50 mg	10's	10's X 10	1200000
418	1794	Salbutamol Rotacaps 200mcg	Each Capsule contains: Salbutamol Sulphate equivalent to Salbutamol 200mcg	30's	30's x 10	2500000
419	1795	Salicylic acid 1.15%w/w, Dithranol 1.15%w/w and Coal Tar 5.3%w/w Ointment	Contains: Salicylic acid 1.15% w/w Dithranol 1.15% w/w Coal Tar 5.3% w/w	30gm Tube	30g tube X 20	1200000
420	1796	Salmeterol 50mcg and Fluticasone Propionate 100mcg Powder for	Each Capsule contains: Salmeterol 50mcg (As Salmeterol Xinafoate IP)	30's	30's x 10	500000

		Inhalation IP	Fluticasone Propionate IP 100mg			
421	1797	Saroglitazar Tablets 4mg	Each Uncoated tablets contains: Saroglitazar 4mg	10's	10's X 10	1200000
422	1798	Satranidazole 300mg and Ofloxacin 200mg Tablets	Each film coated tablets contains: Satranidazole 300mg Ofloxacin 200mg	10's	10's X 10	1200000
423	1808	Spiramycin Tablets 3.0 MIU	Each film Coated Tablets Contains: Spiramycin 3.0 MIU	10's	10's X 10	200000
424	1815	Telmisartan 40mg, Chlorthalidone 6.25mg and Amlodipine 5mg Tablets	Each film coated tablet contains: Telmisartan 40 mg Chlorthalidone 6.25 mg Amlodipine Besilate equivalent to Amlodipine 5 mg	10's	10's X 10	2500000
425	1818	Tetrabenazine Tablets 25mg	Each uncoated tablets contains: Tetrabenzine 25mg	10's	10's X 10	200000
426	1819	Ticagrelor Tablets 90mg	Each film coated tablets contains: Ticagrelor 90mg	10's	10's X 10	10000000
427	1820	Dilute nitroglycerin equivalent to Nitroglycerine 2.5mg	Each Timed release capsule contains: Dilute nitroglycerin equivalent to Nitroglycerine 2.5mg	25's	1 X 10	2500000
428	1822	Tiotropium Powder for Inhalation IP 18mcg	Each capsule contains: Triotropium Bromide monohydrate IP equivalent to tiotropium 18mcg	1's	1's X 10	5000000
429	1823	Tirofiban Hydrochloride I.V. Injection 5mg per 100ml	Each 100 ml contains: Tirofiban Hydrochloride 5mg	100ml Vial	100ml X 10	200000
430	1825	Torsemide 10mg and Spironolactone 50mg Tablets	Each Uncoated Tablet Contains: Torsemide 10mg Spironolactone 50mg	10's	10's X 10	10000000
431	1832	Undenatured Collagen Type II Capsules 40 mg	Each Hard gelatin capsule contains: Undenatured Collagen II 40 mg (Yielding Total Collagen 10 mg) (Yielding Undenatured Collagen Type II 1.2 mg)	10's	10's X 10	2500000
432	1834	Valacyclovir Tablets 1000mg	Each film coated tablet contains : Valacyclovir Hydrochloride equivalent to Valacyclovir 1000mg	3's	3's X 10	1200000
433	1842	Vitamine B Complex injection (IM/IV) Use	Each ampoule contains: Thiamine (Vit. B1) 10mg Riboflavin (Vit. B2) 4mg Nicotinamide 40mg Pyridoxine (Vit. B6) 4mg Dexpanthenol 6mg Biotin 0.5mg Cynocobalamin (Vit. B12) 8mcg	2ml	2ml X 10	10000000
434	1844	Voglibose 0.2mg, Glimepiride 2mg and Metformin Hydrochloride 1000mg (Sustained Release) Tablets	Each Uncoated Bilayered tablet contains: Voglibose 0.2mg Glimepride 2mg Metformin Hydrochloride 1000mg (In sustained Release form)	10's	10's X 10	5000000
435	1845	Voglibose 0.3mg,	Each Uncoated Bilayered tablet	10's	10's X 10	2500000

		Glimepiride 2mg and Metformin Hydrochloride 1000mg (Sustained Release) Tablets	contains: Voglibose 0.3mg Glimepride 2mg Metformin Hydrochloride 1000mg (In sustained Release form)			

Annexure – XIII

{Ref: - clause 19(K)}

For All the tendered drugs, bidder must comply the shelf life of each quoted drugs in accordance with the "Schedule - P" of Drugs and Cosmetics Rules, 1945. In case drug/medicine not covered in Schedule P of Drugs and Cosmetics Rules, 1945, the bidder must supply the drug/medicine with minimum 24 months shelf life.

Note: Bidders have to declare the required shelf-life detail in Para VI of Annexure II.

ANNEXURE- XIV

Ref. Clause No. 1(ii) C
(Shape, Colour, Packing Type etc. of drugs)

i. **In case of Shape and Size of Tablets/ Capsule / unit pack type;** Bidders must supply the drugs/medicines as per market standard.

ii. **In case of Packing type:**

(a) Drugs (Tablet/Capsule etc.) supplied in strips/ Alu-Alu pack shall be in silver colour.

(b) Drugs (Tablet/Capsule) supplied in Blister pack shall be in transparent colour PVC except for light sensitive drugs which must be supplied in amber colour PVC.

Yours faithfully,

Sd/-
Manager (Procurement)
For & on behalf of BPPI
Ph: 011-49431812
